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ABSTRACT 
Virus entry into target cells is mediated by the attachment of viral glycoproteins to cell 
surface receptors. Entry of the hepatitis C virus (HCV) into hepatocytes has been shown to 
require viral glycoprotein dimer E1E2 and the target cell receptor CD81, scavenger receptor-
BI (SR-BI) and the tight junction proteins claudin-1 and occludin in an undefined mechanism. 
In this study, we aim to define the dynamic movements of these proteins in the membrane 
of the polarising hepatocarcinoma cell line HepG2. We further examine the extent to which 
these kinetics are perturbed following addition of the soluble viral glycoproteins sE2 and 
sE1E2, and the small molecule inhibitor of SR-BI ITX5061.  
The results of this study show that the amount of mobile receptor and the speed at which it 
diffuses varies according to its location within the cell. CD81 and claudin-1 are expressed 
equally in the filopodia and plasma membrane, whereas SR-BI is expressed at lower levels in 
the filopodia compared to the plasma membrane. We show that addition of both sE2 and 
sE1E2 has varying affects on both the speed and mobility of CD81 and claudin-1 and that the 
majority of significant effects observed for claudin-1 are observed at areas of potential cell 
contact. Finally, we demonstrate that addition of ITX5061 affects the diffusion coefficient of 
CD81 and CLDN-1 and the amount of mobile SR-BI. Furthermore, the effects on SR-BI are 
limited to areas of cell contact or exploratory regions. In summary, we present data which 
we hope will further current knowledge of the activity of these receptors in relation to their 
role in HCV infection. 
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1.  INTRODUCTION 
 
1.1 Hepatitis C Virus tropism 
The hepatitis C virus (HCV) is an enveloped positive sense single stranded RNA virus of the 
Flaviviridae family, and is a major worldwide cause of liver disease. HCV currently infects 
around 170 million people worldwide, with 60%-80% of new infections becoming persistent 
(Rehermann and Nascimbeni 2005; Dustin and Rice 2007). As a result, unresolved infection is 
a leading cause of repeated liver transplantation and creates a large healthcare burden. 
Currently, the common course of treatment is a period of pegylated interferon-α and 
ribavirin administration which has a relatively low success rate and unpleasant side effects.  
The 9600bp genome of HCV varies across 6 genotypes and transcribes a polyprotein of 
around 3000 amino acids. This polyprotein is cleaved by cellular and viral proteases to form 
the structural proteins core, E1 and E2; and the non-structural proteins NS2-5 and p7 (Figure 
1). HCV virus entry into a target cell involves the interaction of the glycoproteins E1 and E2 
with four receptors on the target cell surface: scavenger receptor BI (SR-BI), CD81, claudin-1 
(CLDN-1) and occludin (section 1.4).                          
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The primary target of HCV is the hepatocytes of the liver, an epithelial cell type with complex 
polarity (Decaens et al. 2008) (Figure 2). Hepatocyte apical membranes form the continuous 
network of bile canaliculi (BC) with the basal pole contacting the sinusoids.  Seperating the 
two poles is the tight junction (TJ) which regulates paracellular diffusion (Farquhar and 
Palade 1963; Claude and Goodenough 1973).  
The polarity of hepatocytes is critical for both liver function and HCV tropism. This study uses 
the HepG2 hepatocarcinoma line, which exhibits many markers of structural and functional 
polarity, including TJ-like structures (reviewed in Decaens et al. 2008).  Recent studies on the 
role of cell polarity on HCV entry demonstrate that agents which reduce the hepatocellular 
polarity of CD81-HepG2 cells increase the efficiency of infection (Mee et al. 2008; Mee et al. 
2009; Mee et al. 2010). 
Figure 1:  The hepatitis C virus genome. The HCV genome encodes both structural and 
non-structural proteins. Adapted from (Anzola and Burgos 2003).  
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1.2 HCV treatment 
All stages of the viral lifecycle may be considered as potential targets for anti-viral agents. 
New direct acting antivirals (DAAs) are protease and polymerase inhibitors, inhibiting the 
actions of the non-structural proteins NS3/4A and NS5B respectively. Promising results have 
been obtained from such drugs; the DAAs telaprevir and boceprevir are currently in phase II 
clinical trials (Asselah and Marcellin). In contrast, the majority of drugs targeting viral entry 
are still in preclinical trials but are an attractive target (Zeisel et al. 2009; Vermehren and 
Sarrazin, 2011). A small number of such drugs including Silibinin (Wagoner et al. 2010) and 
the small molecule inhibitor of SR-BI ITX5061 (Syder et al., 2011) have been reported, and 
the latter is now in clinical trials.  
(a) (b)
BC
Figure 2: Simple epithelial and hepatic polarity. Apical membranes (red), 
basolateral membranes (black), tight junctions (green) .  Simple epithelial 
polarity involves a single apical and basolateral membrane, seperated by a 
tight junction (a). Hepatic polarity is more complex, with several basolateral 
and apical membranes seperated by tight jucntions. Apical membranes on 
adjacent cells form the continuous network of bile canaliculi (b).  Adapted from 
(Decaens et al. 2008).  
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1.3 Mechanisms of HCV entry  
Viral glycoproteins confer attachment via high affinity particle interactions with cell surface 
receptors or molecules. Following this, viruses generally utilise endogenous receptor 
trafficking pathways to internalise. The HCV viral glycoproteins  E1 and E2 are dependent on 
each other for proper folding of the non-covalent heterodimer E1E2   (Patel et al. 2000; 
Cocquerel et al. 2000; Brazzoli et al. 2005). Studies have shown residues in E1 to be involved 
in both fusion with the target cell membrane and virus entry (Lavillette et al. 2007; Li et al. 
2009), whereas the hypervariable region (HVR) 1 of E2 is rapidly mutated during immune 
escape but retains a basic charge (Farci et al. 2000; Callens et al. 2005; von Hahn et al. 2007). 
This suggests a role for HVR1 a role in binding negatively charged glycosaminoglycans (GAGs) 
at the target cell surface (Callens et al. 2005). 
 
1.4 Receptors 
Following low affinity binding of the virus to heparin sulphate proteoglycans (Barth et al. 
2006; Koutsoudakis et al. 2006), GAGs, lectins, and low density lipoprotein (LDL) receptors, 
four receptors have been shown to be essential for HCV entry: SR-BI, CD81, CLDN-1 and 
occludin (Figure 3). 
 
 
 5 
 
 
 
 
 
 
 
1.4.1 CD81 
CD81 (Figure 3a) is expressed in most tissues and was first identified as an HCV receptor due 
to its interaction with E2 (Pileri et al. 1998). Its role was later confirmed by the discovery that 
its expression in the CD81-deficient HepG2 cell line confers infectivity (Zhang et al. 2004; 
Lavillette et al. 2005; Lindenbach et al. 2005).   
CD81 is a tetraspanin and thus contains 4-6 cysteine residues which form critical disulphide 
bonds with the second large extra cellular loop, and these are essential in the CD81-HCV-E2 
interaction (Petracca et al. 2000). Tetraspanins associate with other tetraspanin and non-
Figure 3: The four  essential HCV receptors. The  CD81 (a), SR-BI (b), CLDN-1 (c) and 
occludin (d). The tetraspanin CD81 and tight junction proteins CLDN-1 an occludin 
each contain four transmembrane domains, whereas SR-BI contains only two. The 
extracellular loops (EC) EC1 and EC2 of CD81 are termed small extracellular loops 
(SEL) and large extracellular loop (LEL) respectively (a). CLDN-1 also contains two EC 
loops (b). (Davis, In press).  
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tetraspanin proteins at cholesterol enriched domains to form cell type-specific tetraspanin 
enriched microdomains (TEMs). These exert a wide array of biological functions, including 
signal transduction, cell migration, and membrane remodelling (reviewed in (Boucheix and 
Rubinstein 2001).  
In non-polarised HepG2 cells, CD81 is present uniformly at the plasma membrane and does 
not relocate upon polarisation (Mee, Harris et al. 2009). This expression pattern is similar in 
healthy liver tissue, where it has been reported as mainly basolateral with some canalicular 
localisation (Reynolds et al. 2008; Mee et al. 2009).  
 
1.4.2 SR-BI 
 SR-BI (Figure 3b) is a scavenger protein and is expressed mainly on steroidogenic tissue, 
macrophages, and in the liver (Krieger et al. 2001).  It is involved in the selective uptake of 
cholesterol from ligands such as high density lipoproteins (HDLs) and their particle 
endocytosis or selective transfer to the membrane (reviewed in Fidge 1999).  
SR-BI was identified as an HCV receptor by virtue of its specific interaction with the HVR of 
E2 (Scarselli et al. 2002; Barth et al. 2005), likely facilitated by the HVR-1 domain (Scarselli et 
al. 2002; Bartosch et al. 2003a; Bartosch et al. 2003b; Callens et al. 2005; Voisset et al. 2005).  
Its importance has since been verified using gene silencing and addition of neutralising 
antibodies (Lavillette et al. 2005; von Hahn et al. 2006; Grove et al. 2007;  Dreux and Cosset 
2009). Furthermore, HDLs have been shown to promote HCV infection in an SR-BI dependent 
manner (Bartosch et al., 2005; Meunier et al. 2005; Voisset et al., 2005).   
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In non-polarised HepG2 cells SR-BI is expressed uniformly around the plasma membrane and 
does not relocate upon polarisation (Mee et al. 2009). Again, this reflects the localisation of 
the protein in healthy liver tissue, with presence of the protein at the basolateral membrane 
with minimal staining at canaliculi (Reynolds et al. 2008).  
 
1.4.3 CLDN-1  
In 2007, a study of a permissive hepatocarcinoma cell line highlighted CLDN-1 (Figure 3c) as 
a potential HCV receptor (Evans et al. 2007), with CLDN- 6 and -9 able to compensate if 
CLDN-1 is absent. CLDN-1 is expressed at highest concentrations in the liver, but is also 
present in many other tissues (Furuse et al. 1998).  
Claudins are able to form homo- and heterodimers with each other (Piontek et al. 2008), 
occludin and CD81, (Harris et al. 2010) and the formation of the CD81-CLDN-1 interaction is 
essential for HCV entry (Yang, Qiu et al. 2008; Cukierman et al. 2009; Harris et al. 2010; 
Krieger et al. 2010). These dimers can be formed between proteins on adjacent cells, and 
although no direct interaction between CLDN-1 and the HCV glycoproteins has so far been 
identified, it is thought that cis-interactions between claudins on adjoining cells are involved 
(Liu et al. 2009).  Recent evidence also suggests that CLDN-1 may potentiate the interaction 
between CD81 and E2 (Krieger et al. 2010).  
CLDN-1 has been shown to localise to the PM in non-polarised HepG2 cells and to 
redistribute to TJs on polarisation, with localisation retained but reduced at the basal 
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membrane (Mee et al. 2009). This pattern is similar to that seen in healthy liver tissue 
(Reynolds et al. 2008).  
In healthy liver tissue, SR-BI colocalises with CLDN-1 at the basolateral surface, with minimal 
coexpression at the apical region (Reynolds et al. 2008). In polarised HepG2 cells, CLDN-
colocalises with CD81 at the basolateral membrane, with minimal coexpression at the TJ 
(Harris et al. 2010).  In healthy liver tissue, colocalisation between Cd81 and CLDN-1 is 
strongest at the apical canalicular region (Reynolds et al. 2008). 
 
1.4.4. Occludin  
 Occludin is a tight junction protein, and internalises with CLDN-1 in caveolae and clathrin-
dependent processes (Matsuda et al. 2004; Shen 2008; Stamatovic et al. 2009).  cDNA 
screening identified the tight junction protein occludin (Figure 3d) as necessary to confer 
entry into non-permissive cell lines, and silencing of occludin to reduce infection of 
permissive Huh-7.5 hepatoma cells (Ploss et al. 2009).  Occludin was independently 
identified as an HCV receptor by siRNA silencing of proteins known to associate with CLDN-1 
(Liu et al. 2009).  
In polarised HepG2 cells, occludin localises exclusively to the TJs surrounding the BC, 
replicating the pattern seen in healthy liver tissue (Reynolds et al., 2008; Mee, et al., 2010).  
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1.5 Models of HCV entry  
 
Following initial binding of HCV to the target cell surface, the mechanism of entry is 
controversial, and two mechanisms have been proposed. 
1.5.1 Coxsackie virus B (CVB) entry model 
A large number of viruses have been shown to utilise the TJ as a point of entry (Guttman and 
Finlay 2009), including CVB.  Both CD81 (Brazzoli et al. 2008) and the CVB-receptor complex 
(Coyne et al., 2007) have been observed to move away from the basolateral membrane to 
areas of cell-cell contact during infection.  CVB enters a target cell via the following 
mechanism. The virus interacts with the decay accelerating factor (DAF) on the apical surface 
of the cell and this activates Abl kinase and Fyn kinase. Activation of Abl kinase induces Rac-
dependent actin rearrangements which permit virus movement to the tight junction. Here, it 
interacts with the Coxsackievirus-adenovirus receptor (CAR) (Coyne and Bergelson 2006; 
Coyne et al., 2007). As a result of which conformational changes in the virus capsid are 
induced which are essential for virus entry and RNA release. In contrast, activation of Fyn 
kinase, leads to phosphorylation of caveolin and transport of the virus into the cell inside 
caveolar vesicles (Coyne and Bergelson 2006).   
However, there are a number of differences between CVB and HCV entry:  firstly interaction 
with the TJ  protein CAR is essential for CVB internalization, whereas there is limited 
evidence for direct association of HCV with the TJ proteins claudin-1 or occludin; secondly 
CVB enters via macropinocytosis whereas HCV internalizes by clathrin-dependent endo-
cytosis (Blanchard et al., 2006); and finally, CVB enters via the apical surface whereas it is 
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believed that HCV enters via the basolateral surface of their target cell types (Drummer et 
al., 2011).  
1.5.2 Basolateral entry model  
 
The basolateral entry model is based on the observation that the HCV pseudoparticle system 
(HCVpp) infects the polarised colorectal adenocarcinoma cell line Caco-2 in a polarisation-
dependent but TJ-independent manner (Mee et al. 2008). The lack of dependence on the TJ 
for entry has been further supported by the observation that the CD81-CLDN-1 complex 
which shown to be essential in virus entry is entirely absent from the TJ (Harris et al. 2010). 
Furthermore, reduction in polarity mediated by addition of VEGF promotes HCV entry (Mee 
et al. 2010). Interestingly, it was shown that HCV infection actually modulated   VEGF 
expression, suggesting that HCV infection causes a reduction in polarity (Mee et al. 2010). 
In addition, it has been shown that hepatocyte filopodia extend through the sinusoidal 
membrane and into the sinusoids, where they contact T-cells (Warren et al. 2006) (Figure 4). 
Therefore, filopodia may make initial contacts with the virus here. To support this, DiD-HCV 
has been shown to associate with filopodia and travel along them towards the PM in Huh-
7.5 cells (Coller et al. 2009). In the spread of HIV, long-lived interactions between filopodia-
like structures on a target cell and an HIV-infected cell known as nanotubes have been 
shown to be important in virus transmission (Sowinski et al. 2008).  
Therefore, the basolateral model of entry suggests that HCV enters the liver through the 
sinusoidal blood, encounters the basolateral-sinusoidal forms of the receptors first and 
enters the hepatocytes at this pole.  
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Figure 4: Hepatocyte filopodia extend through the sinusoidal membrane. From (Warren et 
al. 2006). 
 
 
1.6 Project objectives:  
We hypothesise that receptor diffusion will define HCV entry, and aim to cover the following 
points: 
1. To characterise the mobility and diffusion of host cell molecules CD81, SR-BI, CLDN-1 
and occludin in HepG2 cells and to ascertain whether cellular location alters receptor 
trafficking.  
2. To ascertain whether HCV glycoproteins alter receptor mobility.  
3. To define the effect of SR-BI antagonist ITX5601 on protein diffusion. 
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2 MATERIALS AND METHODS  
 
2.1. Cell lines and reagents 
HepG2 cells (ATCC) were propagated in Dulbecco’s modified Eagle’s medium (DMEM, 12491-
023, Invitrogen) supplemented with 10% fetal bovine serum (10500-064, Invitrogen), 1% 
non-essential amino acids (11140-035, Invitrogen), 1% -glutamine (25030, Invitrogen) and 
1% penicllin-streptocmycin (15070063, Invitrogen) at 37°C. 
Soluble (s) E2 and E1E2 (a kind gift from Chiron) were added to fluorescently tagged cells at a 
concentration of   0.7mM, which gave a 90% neutralisation of the HCV cell culture (HCVcc) 
system (data supplied by Chiron, not shown). The cells were then incubated for an hour at 
37°C. Fluorescence recovery after photobleaching (FRAP) of proteins of interest was then 
carried out and analysed as described below (Section 2.4).  
The small molecule inhibitor of SR-BI ITX5061 and the control compound ITX7094 (iTherX,) 
were added to fluorescently tagged cells at a concentration of 5μM (representing 90% 
neutralisation) and incubated for an hour at 37°C. FRAP on proteins of interest was then 
carried out and analysed as described below (Section 2.4). 
 
2.2 Generation of fluorescently-tagged CD81, SR-BI, CDLN-1, occludin and 
glycophosphatidylinositol (GPI) proteins 
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SR-BI, CD81, CLDN-1, occludin and GPI proteins were tagged with the monochorionic 
Aequorea coerulescens green fluorescent protein (AcGFP) tag or a  Discosoma sp. Red 
monomer (DsRED)  as previously described (Harris et al. 2008). These were transfected into 
HepG2 cells using Lipfectamine 200 (Invitrogen) according to manufacturer’s instructions.  
 
2.3 Laser Scanning Confocal Microscopy 
HepG2 cells expressing AcGFP- tagged CD81, CLDN-1, OCLN-1, SR-BI, GPI, or DsRED-tagged 
CD81 were grown on 13-mm glass coverslips.  The cells were imaged live in phenol red-free 
DMEM (11054001, Invitrogen) with 20 mM HEPES (15630049, Invitrogen) on a Zeiss Meta 
head laser scanning 780 confocal microscope with settings optimized for each fluorescent 
protein, and a 100 x1.4 NA oil immersion objective was used. The temperature was 
maintained at 37°C. 
16 bit images were captured at 0.150s/frame, at 1024 pixels2. Using the Zeiss laser scanning 
confocal microscope software, regions of interest were selected were photobleached at 
100% laser strength over 25 iterations to reduce the fluorescence of the fluorescently tagged 
proteins to around 50% of the original. Their recovery was monitored over time (see section 
2.4) using the overlay, profiling and intensity frequency tools of the Zeiss laser scanning 
confocal microscope software. Fluorescence recovery was measured as average signal 
intensity, and the curves generated from background-subtracted and bleaching corrected 
images. Fluorescence signal was normalised to prebleach signals in the same region of 
interest.  
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Out of focus light was reduced by imaging a 0.5μm Z-section at the glass-cell interface using 
pseudo-total internal reflectance fluorescence (TIRF) microscopy. 
2.4 Fluorescence recovery after photobleaching (FRAP) 
The diffusion of proteins within a membrane is altered by a number of factors, including 
membrane composition, fluidity and associations with partner proteins and the 
cytoskeleton. 
FRAP is widely used to find the speed of diffusion (diffusion coefficient), mobile fraction, 
and time to 50% recovery of original intensity (T1/2) of a protein within a membrane. In 
this technique, regions of membrane are bleached to 50% of the original fluorescence 
intensity and the recovery is monitored over time. Bleaching to this level prevents 
phototoxicity of the cell. In this study, the Zeiss Metahead laser scanning confocal 
microscope 780 was used to photobleach a Intensity recovery was then monitored over 
one minute using the Zeiss laser scanning confocal microscope software (Section 2.3). 
It is necessary to take into account the possibility that the protein of interest may also be 
diffusing from within the cell in a process known as intracellular ‘exchange’ (Figure 5). If 
a protein is moving by lateral diffusion, then a small and large bleached area will each 
have a different T1/2. However if the bleached patches are recovering by intracellular 
exchange then the two regions will have the same T1/2.  
By plotting the fluorescence of these bleached areas over time, it is possible to create a 
curve (Figure 6, Equation 1), and providing that the protein is only diffusing by one 
means it is possible to derive the T1/2 (equation 2) and mobile fraction of specific proteins 
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in selected areas (Figure 2). Furthermore, manipulation of the equation of the curve can 
give the diffusion coefficient of the protein (Equation 3).  
 If a protein is diffusing by both exchange and diffusion a more complex double 
exponential formulae will fit the curve more precisely. 
 
  
 
 
 
In this study, the mode of diffusion was established by bleaching a range of sizes of 
regions of interest (ROI, Figure 7a) and observing that the T1/2 was not consistent i.e. the 
Figure 5: Two possible modes of protein diffusion. Lateral diffusion occurs from only 
within the plane of the membrane, where the T1/2 differs between small and large 
bleach spots (a). In exchange, the protein diffuses from intracellular compartments 
and the T1/2 is the same for small and large bleached regions.  
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time taken for half of fluorescence to recover was not consistent between bleached 
regions of difference sizes in the time observed. Any regions of interest that did not fit 
these parameters were excluded.  The only exception to this was occludin, which is 
trafficked to the tight junction from the cytoplasm. However, the fluorescence recovery 
of occludin fitted a single exponential curve and throughout the experiment the 
opportunity for diffusion by exchange was kept to a minimum by imaging a 0.5μm Z-
section at the glass-cell interface using pseudo-TIRF microscopy. 
  
 
 
 
 
(a) 
(b) 
(c) 
(d) 
Figure 6: Plot of diffusion intensity over time.  Initially, a prebleach value for 
the region of interest is recorded (a). Following bleaching (b), intensity recovers 
(c) before reaching a plateau of recovery (d). Plotting the recovery of 
fluorescence and establishing the equation of the resulting curve gives the 
mobile and immobile fractions, T1/2, and diffusion coefficient.  
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2.5 Regions of interest 
The structures examined in this report are detailed below (Figure. 7b). In all cases, 
filopodia are defined as small motile protrusions on the plasma membrane which are 
adhered to the glass surface and attached to the cell at one end only. As they are visible 
using confocal microscopy they are distinct from microvilli, but are smaller in length than 
nanotubes. The structures examined are as follows (Figure 7b): filopodia and plasma 
membrane (PM) in situations where there are no nearby cells (‘free’), PM and filopodia 
in close proximity to another cell (‘exploratory’) and PM at cell junctions (cell contact).  It 
should be noted that in order to qualify as ‘exploratory’ structures, there need not be 
contact between cells at other points. 
Hepatocytes in the liver form intercellular contacts and extend filopodia through the 
sinusoidal membrane into the sinusoidal blood (Figure 4). These two regions are 
represented by ‘contact’ and ‘exploratory’ regions respectively in this study.  
 
Regions of interest selected for bleaching were of various sizes, and more than 10 
regions were bleached per cell (Figure 7a).  
Equation 1: Simple exponential 
Equation 2 
Equation 3: Diffusion Coefficient 
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2.6 Statistical analysis 
Statistical analyses and data representation were carried out using GraphPad Prism software 
(GraphPad software), with significance calculated using one-way ANOVA with a Tukey’s post 
test. Where variances were unequal, the Student’s T test with a Mann-Whitney post test was 
use. The significances are represented as follows: p < 0.05 (*), p< 0.01(**), and p < 0.001 
(***). Unless otherwise stated, the values quoted are medians in order to take into account 
the non-Gaussian distribution of the data.  
  
Figure 7: Representative image of regions of interest and structures examined on a 
HepG2 cell expressing CD81-GFP. Multiple bleach points were used for each structure. 
Image displayed is a HepG2 cell transfected to express AcGFP-CLDN-1 (a). Structures 
examined are as follows: ‘free’ filopodia and plasma membrane (PM), ‘exploratory’ PM 
and filopodia and ‘cell contact’ PM. Regions are displayed on HepG2 cells transfected 
with AcGFP .CLDN-1 and DsRED.CD81 (b) . The cells were imaged on a Zeiss Meta head 
laser scanning 780 confocal microscope. Scale bars are 10 μm. 
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3. DRESULTS  
2.1 Receptor localisation 
HepG2 cells were transfected to express GFP-SR-BI, GFP-CD81, GFP-CLDN-1, GFP-occludin, 
and GFP-GPI. GFP-SR-BI was visible throughout the PM, although there were some areas of 
high PM staining (Figure 8a). However, there was very low expression in the filopodia, which 
were only just visible using confocal microscopy. In contrast, CD81 was visible uniformly 
around the PM with expression in the filopodia similar to that seen in the membrane. Again, 
there were areas of high PM staining (Figure 8b). In polarised cells, CLDN-1 had very high 
expression at the BC-like structure with lower basolateral PM staining (Figure 8c). Occludin 
had a distinctive expression pattern, with expression only visible at the tight junction around 
the BC-like structure (Figure 8d). The control protein GPI was visible uniformly throughout 
the membrane, with expression on all membranes (Figure 8e).  
 
 
 
 
 
Figure 8 : Representative images of receptor localisation. Representative images of 
HepG2 cells transfected to express AcGFP-SRB-1(a), DsRed-CD81(b), AcGFP-CLDN-1(c), 
AcGFP-occludin (d), and AcGFP-GPI (e). The cells were imaged on a Zeiss Meta head laser 
scanning 780 confocal microscope. Scale bars are 10 μm.  
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3.2 Variance between individual cells within a sample 
In order to examine the variance between cells within a sample, the diffusion coefficients 
and mobile fractions of CD81 were compared at both the plasma membrane and filopodia in 
10 CD81-HepG2 cells (Figure 9). At both locations the diffusion coefficient appeared to vary 
widely between the samples, with a range of 0.02 μm2/s to 1.5 μm2/s in the filopodia and 
0.02 μm2/s to 1.7 μm2/s in the PM (Figure 9 a, c).  The mobile fraction also varied between 
cells within the sample (Figure 9 b, d) with mobile fractions ranging between 7.5% and 97% 
in the PM and 2.7% and 95.9% in the filopodia. These data show considerable variation in 
receptor kinetics between cells within a sample, and may represent multiple populations of 
protein as defined by different kinetics.  
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Figure 9:  Variance in diffusion coefficient and diffusion coefficient between cells in 
a sample. Diffusion coefficient (a, c) and mobile fraction (c,d) at the PM ( a, b) and 
filopodia (c, d)between 10  HepG2 cells transfected to express GFP-CD81. Diffusion 
coefficient and mobile fraction were calculated using Zeiss software. Each bar 
represents the values for one cell, with more than 1 bleached spot per cell.  Error bars 
represent SEM.  
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3.3 Differences in receptor dynamics between the PM and filopodia 
As it is possible that protein dynamics vary at different locations within in the cell, the 
diffusion coefficient and mobile fraction of the AcGFP-tagged proteins SRB1, CD81, CLDN-1 
and occludin were measured in the plasma membrane and filopodia in HepG2 cells using 
FRAP. In addition, the lipid raft marker GPI was used as a non-HCV control (Figure 10).  
Neither the diffusion coefficient nor mobile fraction of SR-BI varied significantly between the 
PM and filopodia. The median diffusion coefficients at the PM and filopodia were 0.25 μm2/s 
and 0.22 μm2/s respectively, and the mobile fractions 50.48% and 44.83% respectively. 
However, the diffusion coefficient appeared to display less variability than the mobile 
fraction between samples in both the PM and filopodia (Figure 10, Table 1).    
The diffusion coefficient of CD81 at the filopodia was significantly higher than that in PM 
(Figure 10), with medians of 0.23 μm2/s and 0.36 μm2/s respectively, although the mobile 
fraction appeared lower at the latter with 55.6% of CD81 mobile at the PM compared to 
41.14% at the filopodia (Table 1). Therefore, whilst the speed of diffusion of CD81 is greater 
in the filopodia, the mobility of the protein is reduced.  
The mobile fraction of CLDN-1 showed a significantly larger variation in the filopodia than in 
the PM, whose values were more closely grouped at both regions than that of the mobile 
fraction. Again, the variance in diffusion coefficient was lower (Figure 10). Both diffusion 
coefficient and mobile fraction were significantly lower in the filopodia than the PM (Figure 
10), with a median of 74.67% mobile at the PM and 53.27% at the filopodia, and median 
diffusion speeds of 0.35 μm2/s at the PM and 0.24 μm2/s at the filopodia (Table 1). This 
shows that both the speed and percentage of mobile CLDN-1 is reduced at the filopodia.  
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Data for GPI and occludin are presented in the appendix (Supplementary Figure 1, 
supplementary Table 1). Few data points were recorded for occludin as very few bleached 
areas recovered in the observation time. There was no significant difference in either 
diffusion coefficient or mobile fraction between the two structures at which occludin was 
visible – the plasma membrane and tight junction (Supplementary Figure 1). The data for the 
control protein GPI was very variable but displayed significant difference in both parameters 
(Supplementary Figure 1), with the mobile fraction appearing to be lower in the filopodia yet 
having a greater diffusion speed.  The median mobile fraction of GPI at the PM was 64.94% 
with a median diffusion coefficient of 0.06 μm2/s, and the median mobile fraction at the 
filopodia was 50.47% with a median diffusion coefficient of 0.02 μm2/s (supplementary Table 
1). 
Therefore, receptor mobility and diffusion speed differ between intracellular sites, although 
the way in which these differ depends on the receptor. CLDN-1 and CD81 are particularly 
variable, whilst SR-BI is less so. 
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Figure 10: Variance in diffusion coefficient and mobile fraction between PM and 
filopodia. HepG2 cells were transfected to express GFP-SR-BI, GFP-CD81, DsRed-CD81, 
and GFP-CLDN-1 and bleached using a Zeiss Meta head laser scanning 780 confocal 
microscope.  Diffusion coefficient and mobile fraction using data from Zeiss software. 
Each symbol represents one cell, n>21, with more than 1 bleached region per cell.  
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Receptor/ 
paremeter
Structure
Median
(IQ range)
Mean S.D
SR-B1  
Diffusion 
coefficient 
(μm2/s)
PM 0.25 (0.28) 0.29 0.22
FIlopodia 0.22 (0.22) 0.26 0.18
SR-B1 mobile
fraction (%)
PM 50.48 (28.7) 51.5 21
Filopodia 44.83 (23.76) 46 20.92
CD81 diffusion 
coefficient 
(μm2/s)
PM 0.23 (0.30) 0.34 0.32
Filopodia 0.36 (0.83) 0.53 0.47
CD81 mobile
fraction (%)
PM 55.6 (26.92) 53.77 20.29
FIlopodia 41.12 (33.55) 46.48 23.95
CLDN-1 
diffusion
coefficient 
(μm2/s)
PM 0.35 (0.23) 0.35 0.18
Filopodia 0.24 (0.09) 0.22 0.09
CLDN-1 mobile 
fraction (%)
PM 74.67 (11.67) 74.5 10.54
Filopodia 53.27 (31.52) 50.19 19.86
Table 1: Median, interquartile range (IQ range), mean, and standard deviation (S.D) 
of data presented in Figure 10. HepG2 cells were transfected to express GFP-SR-BI, 
GFP-CD81, DsRed-CD81, and GFP-CLDN-1 and bleached using a Zeiss Meta head laser 
scanning 780 confocal microscope. Statistics were calculated using data from Zeiss 
software. n>21.Values calculated using GraphPad Prism Software.  
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3.4 Differences in receptor dynamics between specific cellular locations 
The large variances in receptor dynamics within the samples led us to examine the diffusion 
coefficient and mobility of the proteins in the PM and filopodia at areas of cell contact and 
exploratory regions as these may represent distinct ‘pools’ of receptors.   
Again, there were no significant differences in the dynamics of SR-BI at more defined cellular 
locations. Also, the variability in results appeared to be greater in the mobile fraction, 
particularly at the exploratory PM edge (Figure 11, Table 2).  
The variability in the diffusion coefficient of CD81 described in Figure 10 at the plasma 
membrane may be explained by the presence of two apparently separate pools of CD81– 
that at the exploratory membrane and that at the cell contact membrane. The latter was 
significantly higher than that at the exploratory membrane with a median diffusion 
coefficient of 0.45 μm2/s in comparison to 0.19 μm2/s at the exploratory PM (Table 2). This is 
matched by a non-significant increase in the mobile fraction of CD81 at the same region. 
However, mobile fraction data displayed large variability. 
The data presented in Figure 10 show the variance of diffusion speed and mobile fraction of 
CLDN-1 between cells to be relatively low, suggesting that unlike CD81 there is only one pool 
of CLDN-1 as defined by receptor dynamics. Analysis of CLDN-1 mobility and diffusion speed 
at cell contact and exploratory filopodia and PM supported this hypothesis, and show that 
there are not multiple populations of CLDN-1 at the regions investigated. 
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As occludin was only visible at the TJs and at low levels in areas of cell contact its kinetics at 
more defined regions could not be examined (Supplementary Table 2). Again, the data for 
GPI is displayed in the appendix (Supplementary Figure 2, supplementary Table 2). Both the 
diffusion coefficient and mobile fraction of GPI were observed to be higher at the cell 
contact PM (median diffusion speed 0.04 μm2/s and mobile fraction 79.33%) than the 
filopodia (median diffusion speed 0.003 μm2/s and mobile fraction 50.4%) (Supplementary 
figure 2, Supplementary Table 2).  
These data show that the speed of diffusion of CD81 is significantly higher in areas of cell 
contact, whereas other HCV receptors show no such significant diversity in dynamics 
between cellular sites. 
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) Figure 11: Diffusion coefficient and mobile fraction of receptors at specific cellular 
structures. Diffusion coefficient and mobile fraction measured in HepG2 cells 
transfected to express GFP-SR-BI, GFP-CD81, DsRed-CD81, and GFP-CLDN-1 at specific 
l cations. Cells were bleached using a Zeiss Meta head laser scanning 780 confocal 
microscope and diffusion coefficient and mobile fraction were calculated using data 
from Zeiss software. n>21, with more than 1 bleached region per cell.  White bars 
represent exploratory filopodia, light grey exploratory PM, and dark grey cell contact 
PM.  
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Structure Median (I.Q range) Mean S.D.
SR-B1 
Diffusion 
Coefficient 
(μm2/s
Exploratory PM 0.13 (0.31) 0.16 0.15
Exploratory 
filopodia
0.04 (0.19) 0.11 0.16
Cell contact PM 0.21 (0.33) 0.26 0.26
SR-B1 Mobile 
Fraction (%)
Exploratory PM 63.29 (27.67) 67.49 18.64
Exploratory 
Filopodia
37.73 (9.11) 40.07 6.97
Cell Contact PM 74.67 (13.52) 70.84 13.28
CD81 
Diffusion 
Coefficient 
(μm2/s)
Exploratory PM 0.19 (0.34) 0.25 0.21
Exploratory 
filopodia
0.10 (0.34) 0.21 0.22
Cell contact PM 0.45 (0.69) 0.57 0.45
CD81 Mobile 
fraction (%)
Exploratory PM 56.13 (32.84) 57.1 21.72
Exploratory 
filopodia
49.74 (31.55) 51.18 22.3
Cell contact PM 62.09 (22.17) 62.51 17.25
CLDN-1 
Diffusion 
Coefficient 
(μm2/s)
Exploratory PM 0.36 (0) 0.42 0.13
Exploratory 
filopodia
0.33 (0) 0.24 0.17
Cell Contact PM 
Edge
0.44 (0.36) 0.51 0.22
CLDN-1 
Mobile 
Fraction (%)
Exploratory PM 77.64 (19.45) 75.69 10.66
Exploratory 
filopodia
29.96 (0) 35.96 30.64
Cell contact PM 73.86 (18.72) 74.5 13.63
Table 2: Median, interquartile range (IQ range), mean, and standard deviation (S.D) 
of data presented in Figure 11. HepG2 cells were transfected to express GFP-SR-BI, 
GFP-CD81, DsRed-CD81, and GFP-CLDN-1 and bleached using a Zeiss  Meta head laser 
scanning 780 confocal microscope, n>21.  Diffusion coefficient and mobile fraction were 
calculated using data from Zeiss software.Values calculated using GraphPad Prism 
Software.  
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3.5 Addition of viral glycoproteins 
We were interested in whether addition of viral glycoproteins would alter the diffusion 
speed or mobility of HCV receptors. Therefore, we added the soluble viral glycoproteins sE2 
(0.7mM) and sE1E2 (0.7mM) to cells expressing GFP-CLDN-1 or GFP/DsRed-CD81. 
When looking at the effect of addition of sE2 and sE1E2 on filopodia and PM only, addition 
of sE2 caused a decrease in mobile fraction of both CD81 and CLDN-1, whereas addition of 
sE1E2 caused an increase in the diffusion coefficient of the filopodia (Figure 12). 
However, when the regions of interest were expanded to include areas of exploratory 
regions and areas of cell contact, it became evident that the majority of the effects 
conferred by addition of the viral glycoproteins was on CLDN-1, particularly at areas of 
exploratory and cell contact rather than at ‘free’ regions (Table 3b).   
Following addition of sE1E2, the mobile fraction of CLDN-1 was increased at the exploratory 
filopodia and exploratory PM from 48.08% to 72.72% and 48% to 62.37% respectively. In 
contrast, addition of sE1E2 decreased the diffusion coefficient of exploratory filopodia from 
0.91 μm2/s to 0.06 μm2/s (Table 3b).  
 Addition of sE2 also caused a decrease in the mobile fraction of CLDN-1 at the exploratory 
PM and exploratory filopodia, with values decreasing from 0.91 μm2/s to 0.09 μm2/s and 
0.30 to 0.05 μm2/s respectively. However, addition of sE2 did not exclusively cause 
decreases in diffusion coefficient, as addition of sE2 increased the diffusion coefficient of 
CLDN-1 from 0.09 μm2/s to 0.54 μm2/s at filopodia (Table 3b). 
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In contrast, the affects of addition of glycoproteins to cells expressing CD81 were not so 
varied, and were limited to the mobile fraction (Table 3a). Here, addition of sE1E2 caused a 
small but significant decrease in the mobile fraction at the filopodia from 61.74% to 60.20%. 
Addition of sE2 alone caused a decrease in mobile fraction of the protein from 68.23% to 
56.84% (Table 3a).   
During analysis it became evident that HepG2 cells expressing CD81 displayed small regions 
of high protein expression. As CD81 forms part of TEMs, we examined the diffusion 
parameters of CD81 at these regions, although they have not been identified as TEMs. When 
looking at these areas of high CD81 expression, addition of E2 significantly increased the 
mobile fraction at areas of high protein expression from 46.03% to 55.33% (Table 3a).  
These data show that addition of the viral glycoproteins does cause a change in receptor 
movement, particularly CLDN-1 at exploratory regions.  
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Figure 12 : Diffusion coefficient and mobile fraction of CD81 and CLDN-1 
following addition of viral glycoproteins. Diffusion coefficient and mobile 
fraction measured in HepG2 cells transfected to express GFP-CD81, DsRed-CD81, 
and GFP-CLDN-1 at specific locations after the addition of the glycoproteins sE2 
and sE1E2 at 0.7 mM. Cells were bleached using a Zeiss  Meta head laser 
scanning 780 confocal microscope. Diffusion coefficient and mobile fraction were 
calculated using data from Zeiss software. n>15, with more than one bleached 
region per cell. White bars correspond to untreated samples, light grey to 
addition of sE2 and dark grey to addition of sE1E2.  
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Median (IQ range) Mean S.D Significance
C
D
81
 D
if
fu
si
o
n
 C
o
e
ff
ic
ie
n
t μ
m
/s
 
High PM
Control 0.16 (0.19) 0.21 0.23
sE2 0.35 (0.21) 0.36 0.12
sE1E2 0.20 (0.40) 0.28 0.23
PM
Control 0.11 (0.11) 0.16 0.13
sE2 0.10 (0.13) 0.15 0.17
sE1E2 0.17 (0.12) 0.19 0.06
Filopodia
Control 0.16 (0.37) 0.55 1.16
sE2 0.07 (0.03) 0.09 0.05
sE1E2 0.35 (0.27) 0.34 0.21
Exploratory filopodia
Control 0.54 (0.00) 0.54 0.29
sE2 0.05 (0.07) 0.06 0.04
sE1E2 0.10 (0.00) 0.18 0.20
Exploratory PM
Control 0.07 (0.86) 0.39 0.53
sE2 0.15 (0.29) 0.21 0.16
sE1E2 0.13 (0.11) 0.13 0.08
Cell contact PM
Control 0.16 (0.19) 0.21 0.15
sE2 0.19 (0.28) 0.24 0.19
sE1E2 0.33 (0.49) 0.41 0.37
C
D
81
 M
o
b
ile
 F
ra
ct
io
n
 (
%
) 
High PM
Control 46.03 (10.28) 45.81 10.96
sE2 64.77 (20.87) 61.10 11.33
sE1E2 55.22 (32.53) 55.73 19.11 * 
PM
Control 56.11 (23.62) 50.92 11.93
sE2 49.26 (20.09) 42.67 15.02
sE1E2 65.14 (9.00) 64.16 10.17
Filopodia
Control 61.74 (36.36) 71.86 19.80
sE2 51.44 (12.33) 50.14 9.93
sE1E2 60.20 (15.48) 58.20 11.57 ** 
Exploratory filopodia
Control 57.16 (0.00) 59.99 17.11
sE2 18.27 (21.67) 23.40 12.31
sE1E2 75.94 (0.00) 72.33 16.41
Exploratory PM
Control 53.70 (33.26) 47.29 17.35
sE2 37.51 (10.03) 38.56 5.22
sE1E2 57.68 (9.58) 58.19 6.21
Cell contact PM
Control 68.23 (11.44) 70.04 10.97
sE2 56.84 (37.85) 66.91 20.42 ** 
sE1E2 68.74 (22.89) 65.37 14.06
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Table 3a: Median, interquartile range (IQ range), mean, and standard deviation (S.D) of 
CD81 following addition of sE2 and sE1E2. Diffusion coefficient and mobile fraction of CD81 
at various cellular locations following addition of viral glycoproteins to HepG2 cells 
transfected to express AcGFP-CD81 and Ds-RED CD81.  
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Structure.compound Median (IQ Range) Mean S.D. Significance
C
LD
N
-1
 D
if
fu
si
o
n
 C
o
e
ff
ic
ie
n
t (
μ
m
2
/s
)
PM
Control 0.13 (0.24) 0.1596 0.1289
sE2 0.10 (0.16) 0.1356 0.1144
sE1E2 0.15 (0.16) 0.1678 0.1167
Filopodia
Control 0.09 (0.09) 0.07363 0.04763
sE2 0.54 (1.18) 0.6957 0.5723 **
sE1E2 0.23 (0.33) 0.2435 0.2086
Exploratory filopodia
Control 0.30 (0) 0.5455 0.4993
sE2 0.05 (0.20) 0.1036 0.09757 *
sE1E2 0.37 (0) 0.4071 0.1276
Exploratory PM
Control 0.91 (1.28) 0.9595 0.751
sE2 0.09 (0.11) 0.09265 0.07248 *
sE1E2 0.06 (0.05) 0.07648 0.03999 *
Cell contact PM
Control 0.13 (0.29) 0.1761 0.1448
sE2 0.06 (0.07) 0.05474 0.03282
sE1E2 0.07 (0.16) 0.09134 0.08051
C
LD
N
-1
 M
o
b
ile
 F
ra
ct
io
n
 (
%
)
PM
Control 55.72 (25.65) 53.27 16.11
sE2 45.41 (25.64) 45.55 14.39
sE1E2 56.51 (17.67) 52.69 16.18
Filopodia
Control 59.33 (14.92) 61.77 11.24
sE2 42.41 (13.8) 43.24 9.168
sE1E2 41.95 (20.63) 37.45 13.57
Exploratory filopodia
Control 46.08 (0) 46.41 5.19
sE2 11.06 (9.12) 15.91 11.01
sE1E2 72.72 (0) 69.24 20.38 ***
Exploratory PM
Control 48 (17.79) 50.29 9.255
sE2 31.12 (17.06) 33.65 9.198
sE1E2 62.37 (11.21) 61.42 7.454 *
Cell contact PM
Control 70.66 (8.53) 71.09 6.072
sE2 57.66 (40.82) 48.45 25.42
sE1E2 43.16 (20.76) 41.82 16.48
Table 3b: Median, interquartile range (IQ range), mean, and standard deviation 
(S.D) CLDN-1 following addition of sE2 and sE1E2. Diffusion coefficient and mobile 
fraction of CLDN-1 at various cellular locations following addition of viral 
glycoproteins in HepG2 cells transfected to express AcGFP-CLDN-1.  
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3.6   Addition of ITX5061 and ITX7094 
The small molecule inhibitor ITX5061 has been shown to reduce infection in an SR-BI 
dependent manner (Syder et al. 2011). This compound and the corresponding control 
compound ITX7094 were added to cells expressing GFP-SR-BI, GFP-CLDN-1, GFP and DsRed-
CD81. The mobile fraction and diffusion coefficients of these proteins were examined after 
an hour of incubation with the compound.  
When looking at the PM and filopodia alone, addition of ITX5061 appeared only to affect the 
kinetics protein at the PM of SR-BI, CD81, and CLDN-1(Figure 13), with addition decreasing 
the mobile fraction of SR-BI at this region but increasing the diffusion coefficient of both 
CD81 and CLDN-1 at the PM (Figure 13). However when the regions were expanded to 
include exploratory and cell contact regions, many additional effects were observed.  
Addition of ITX5061 caused a decrease in mobile fraction of SR-BI in three regions; at the 
exploratory PM from 45.68% to 34.13%; exploratory filopodia from 41.71% to 32.34%; and 
at the cell contact PM from 57.72 % to 33.18% (Table 4a). In contrast, the effects on CD81 
and CLDN-1 were only on the diffusion coefficients of the protein, which in all cases resulted 
in an increase. Addition of ITX5061 increased the diffusion coefficients of both CD81 and 
CLDN-1 at the exploratory filopodia (Table 4b, c), but CD81 only at filopodia and areas of low 
expression and CLDN-1 only at the plasma membrane and exploratory PM Figure 4 (Table 
4b, c). 
Addition of sE1E2 or sE2 alone had no effect on CD81 at areas of high CD81 expression, the 
putative TEMs (Table 4b).  
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Therefore, we show that the effects of addition of the small molecule SR-BI inhibitor ITX5061 
are not restricted to SR-BI, but the effects on this protein is distinct the effects of the drug on 
CD81 and CLDN-1. 
 
 
 
 38 
 
 
  
0
25
50
75
100
ITX7960
ITX5061
*
Filopodia PM
M
o
b
il
e
 F
ra
c
ti
o
n
 (
%
)
0.0
0.5
1.0
1.5
Filopodia PM
D
if
fu
s
io
n
 C
o
e
ff
ic
ie
n
t 
(
m
2
/s
)
SR-B1
0
25
50
75
100
Filopodia PM
CD81
0.0
0.5
1.0
1.5
Filopodia PM
***
D
if
fu
s
io
n
 C
o
e
ff
ic
ie
n
t 
(
m
2
/s
)
0
25
50
75
100
Filopodia PM
M
o
b
il
e
 F
ra
c
ti
o
n
 (
%
)
0.0
0.5
1.0
1.5
Filopodia PM
***
D
if
fu
s
io
n
 C
o
e
ff
ic
ie
n
t 
(
m
2
/s
)
CLDN-1
0
25
50
75
100
ITX7960
ITX5061
*
Filopodia PM
M
o
b
il
e
 F
ra
c
ti
o
n
 (
%
)
0
25
0
5
100
Filopodia PM
M
o
b
il
e
 F
ra
c
ti
o
n
 (
%
)
Figure 13: Diffusion coefficient and mobile fraction of CD81 and CLDN-1 following 
addition of ITX5061 and ITX7904. Variance in diffusion coefficient and mobile fraction 
between HepG2 cells transfected to express GFP-SR-BI, GFP-CD81, DsRed-CD81, and  
GFP-CLDN-1 at  specific locations after the addition of ITX5061 and ITX7904. Cells were 
bleached using a Zeiss  Meta head laser scanning 780 confocal microscope n>15, with 
more than 1 bleached spot per cell. Diffusion coefficient and mobile fraction were 
calculated as  previously escribed using data from Zeiss software. White bars 
represent addition of ITX7904, and light grey bars addition of ITX5061.  
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Structure/compound Median (IQ range) Mean S.D Significance
SR
-B
I D
if
fu
si
o
n
 C
o
e
ff
ic
ie
n
t (
μ
m
2
/s
)
PM
ITX7904 0.17 (0.22) 0.22 0.16
ITX5061 0.27 (0.21) 0.34 0.24
Filopodia
ITX7904 0.21 (0.17) 0.27 0.22
ITX5061 0.18 (0.17) 0.22 0.11
Exploratory filopodia
ITX7904 0.04 (0.00) 0.04 0.00
ITX5061 0.07 (0.13) 0.09 0.07
Exploratory PM
ITX7904 0.44 (0.52) 0.45 0.25
ITX5061 0.22 (0.40) 0.32 0.29
Cell contact PM
ITX7904 0.25 (0.40) 0.27 0.20
ITX5061 0.24 (0.30) 0.27 0.30
SR
-B
I M
o
b
ile
 F
ra
ct
io
n
 (%
)
PM
ITX7904 48.86 (16.01) 44.01 11.98
ITX5061 48.85 (18.19) 50.86 11.14
Filopodia
ITX7904 43.59 (9.91) 47.98 11.04
ITX5061 51.14 (10.86) 49.82 6.153
Exploratory filopodia
ITX7904 41.71 (12.68) 44.14 21.59
ITX5061 32.34 (11.19) 32.18 7.488 *
Exploratory PM
ITX7904 45.68 (17.39) 46.6 13.23
ITX5061 34.13 (14.77) 33.92 12.27 *
Cell contact PM
ITX7904 57.72 (18.33) 63.23 17.09
ITX5061 33.18 (13.69) 36.25 10.75 ***
Table 4a: Median, interquartile range (IQ range), mean, and standard deviation 
(S.D) of SR-BI following addition of ITX5061 and ITX7904. Diffuison coefficient and 
mobile fraction of SR-BI at various cellular locations following addition of ITX5061 
and ITX 7904 HepG2 cells transfected to express GFP-SR-BI.  
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Median (IQ range) Mean S.D. Significance
C
d
81
 D
if
fu
si
o
n
 C
o
e
ff
ic
ie
n
t (
μ
m
2 /
s)
High PM
ITX7904 0.24 (0.19) 0.286 0.1436
ITX5061 0.41 (0.17) 0.401 0.1015
PM
ITX7904 0.13 (0.19) 0.168 0.1291
ITX5061 0.21 (0.24) 0.293 0.3743 *
Filopodia
ITX7904 0.15 (0.12) 0.188 0.1748
ITX5061 0.30 (0.30) 0.286 0.1826
Exploratory filoopodia
ITX7904 0.10 (0.19) 0.253 0.3974
ITX5061 0.41 (0.64) 0.557 0.4761 *
Exploratory PM
ITX7904 0.20 (0.27) 0.333 0.3202
ITX5061 0.37 (0.77) 0.567 0.5426 *
Cell contact PM
ITX7904 0.35 (0.17) 0.365 0.1516
ITX5061 0.42 (0.40) 0.547 0.4818
C
D
81
 M
o
b
ile
 F
ra
ct
io
n
 (
%
)
High  PM
ITX7904 60.40 (4.54) 59.54 3.616
ITX7904 55.95 (14.51) 55.22 8.77
PM
ITX7904 55.36 (13.78) 52.93 9.308
ITX5061 54.94 (18.52) 58.13 12.15
Filopodia
ITX7904 50.91 (16.14) 49.72 11.94
ITX5061 55.35 (10.88) 56.44 11.95
Exploratory PM
ITX7904 43.54 (15.9) 43.25 13.23
ITX5061 47.2 (17.62) 46.71 12.69
Exploratory Filopodia
ITX7904 38.14 (20.38) 43.51 21.48
ITX5061 33.92 (23.87) 37.93 14.97
Cell contact PM
ITX7904 36.23 (15.11) 36.54 12.75
ITX5061 39.84 (10.22) 41.48 11.47
Table 4b: Median, interquartile range (IQ range), mean, and standard deviation (S.D) 
of CD81 following addition of ITX5061 and ITX7904. Diffusion coefficient and mobile 
fraction of CD81 at various cellular locations following addition of ITX5061 and ITX7904 
HepG2 cells transfected to express GFP-CD81.  
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Median (IG range) Mean S.D> Significance
C
LD
N
-1
 D
if
fu
si
o
n
 C
o
e
ff
ic
ie
n
t (
μ
m
2
/s
)
PM
ITX7904 0.19 (0.13) 0.2369 0.1449
ITX5061 0.34 (0.28) 0.3541 0.2194 *
Filopodia
ITX7904 0.33 (0.39) 0.385 0.2705
ITX5061 0.34 (0.39) 0.4641 0.3049
Exploratory filopodia
ITX7904 0.15 (0.20) 0.1703 0.1433
ITX5061 0.45 (0.24) 0.521 0.1837 *
Exploratory PM
ITX7904 0.04 (0.16) 0.1111 0.1436
ITX5061 0.39 (0.31) 0.4227 0.2203 **
Cell Contact PM
ITX7904 0.28 (0.20) 0.2782 0.1501
ITX5061 0.39 (0.82) 0.5355 0.5069
C
LD
N
-1
 M
o
b
ile
 F
ra
ct
io
n
 (
%
)
PM
ITX7904 57.96 (13.83) 56.24 10.89
ITX5061 50.72 (17.28) 49.21 10.3
Filopodia
ITX7904 53.42 (18.63) 53.52 12.59
ITX5061 53.75 (20.23) 55.5 11.85
Exploratory filopodia
ITX7904 44.95 (0) 43.15 3.95
ITX5061 47.59 (24.24) 45.8 14.62
Exploratory PM
ITX7904 55.76 (29.42) 53.68 15.28
ITX5061 58.96 (34) 56.08 17.85
Cell Contact PM
ITX7904 38.21 (12.06) 39.57 12.06
ITX5061 42.29 (9.85) 42.04 5.746
Table 4c: Median, interquartile range (IQ range), mean, and standard deviation (S.D) 
CLDN-1 following addition of ITX5061 and ITX7904. Diffusion coefficient and mobile 
fraction of CLDN-1 at various cellular locations following addition of ITX5061 and 
ITX7904 HepG2 cells transfected to express GFP-CLDN-1.  
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4 DISCUSSION 
This study aimed to define the kinetics of the essential HCV receptors SR-BI, CD81, CLDN-1 
and occludin in HepG2 cells. Furthermore, we aimed to discern the effects of addition of the 
viral glycoproteins sE2 and sE1E2 and the small molecule inhibitor ITX5061. 
4.1 Protein localisation 
The results of this report show all SR-BI, CD81, CLDN-1 and occludin to be localised in HepG2 
cells as previously reported (Mee et al. 2009). Both SR-BI and CD81 were visible throughout 
the cell membrane, whereas CLDN-1 was shown to be localised at high levels at the TJ/ BC-
like region and at lower levels in the basolateral membrane. Additionally, occludin was 
localised exclusively to TJs. 
SR-BI showed poor expression in filopodia in HepG2 cells in comparison to that the plasma 
membrane (Figure 8). In non-polarised Huh-7.5 cells DiD-HCV particles have been reported 
to initially bind to filopodia and travel along them to the plasma membrane, as has been 
reported for other viruses and cell types (Duus et al., 2004; Smith and Helenius, 2004; 
Lehmann et al., 2005,  Schelhaas et al.,  2008; Coller et al., 2009). It is possible that SR-BI is 
necessary at an early stage in the infection process for delipidating the virus particle and 
allowing cell surface receptors access to the viral glycoprotein complex E1E2. Therefore, the 
low level of SR-BI observed suggests one of three possibilities: binding of glycoproteins to 
HepG2 cells does not require transport along filopodia (1); in in vitro assays using HepG2 
cells, glycoproteins bind to another receptor first in the filopodia, before binding to SR-BI (2); 
in HepG2 cells, transport of HCV glycoproteins along filopodia does not occur (3). 
Continuation of this study could quantitatively assess the effect of glycoprotein addition on 
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SR-BI protein levels at the filopodia in HepG2 cells, and look for binding of fluorescently 
tagged virus particles to filopodia.  
 
In addition, SRB1 has been shown to be particularly important in cell-cell transmission, 
whereas CD81 and CLDN-1 have similar much the same levels of importance in both cell-cell 
and cell free transmission (Brimacombe et al. 2011). As filopodia would not be present at 
areas of cell contact, SR-BI may be preferentially localised to other sites. Again, further work 
could examine SRB-1 levels at specific sites and quantitatively observe the changes in these 
levels on addition of HCV glycoproteins or fluorescent virus.  
 
The actin cytoskeleton is central to the formation of filopodia, which are formed 
downstream of Cdc42 and Rif (Ridley et al., 2011). Little is known about the membrane of 
filopodia with regards to its composition and receptor expression, but it is possible that such 
a structure may express a different receptor profile to the rest of the cell.  
The results presented here show that although there is no significant change in SR-BI 
dynamics between the PM and filopodia, there is a small decrease at the filopodia which 
could be further examined.   
The diffusion coefficient of CD81 was shown to be higher in the filopodia than at the PM, 
whereas CLDN-1 was the opposite. However, two had a relatively similar diffusion speed in 
the PM, and therefore the receptor complexes formed by CD81 and CLDN-1 may be 
separated in the filopodia.  
To examine the possibility of the CD81-CLDN-1 complex being separated, fluorescence 
resonance energy transfer (FRET) could be used to investigate the relationship between the 
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two at PM and filopodia. Investigation of the role of actin dynamics would be interesting, 
and perturbation of actin polymerisation could be achieved by the addition of cytochalasin D 
or similar compound.  
 
4.2 Protein diffusion kinetics 
 
The diffusion coefficient and mobile fraction of CD81 and SR-BI have not previously been 
reported, although that of the close relative of CD81, CD9, has (Espenel et al. 2008). Using 
the protastic carcinoma cell line PC3, the diffusion coefficient of CD9 was shown to be 0.23 
+/-0.15 μm2/s.  This data corresponds with that seen in this study for CD81 diffusion at the 
PM (Table 5). This study also examined the diffusion coefficient of CD46, which is not 
present in TEMs or rafts, and therefore it may be used as a comparison for SR-BI. The 
diffusion coefficient of CD46 was 0.13 μm2/s +/- 0.08 μm2/s. This is lower than that seen in 
this study for SR-BI, likely due to significant differences in association with other components 
of the cell membrane along with cell type differences.  
Observation of occludin showed the protein to be very static within the tight junction (Table 
5), in direct contrast to recent paper (Shen et al., 2008) using MDCK cells. MDCK cells 
overexpressing EMK1 may be used as a model for looking at hepatic phenotype (Cohen et al. 
2004). However, the cells used in that study did not overexpress EMK1, and therefore may 
form a functionally different TJ structure.   
Again, the figures quoted for CLDN-1 show a more restricted diffusion pattern for the 
protein than observed in this study, and this may be due to cell-type specific differences. 
However, despite showing a higher diffusion coefficient in HepG2 cells (0.26 μm2/s) in 
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comparison to MDCK cells (0.01 μm2/s); the mobile fractions at the tight junction were 
similar between the two cell types. 33.14% of CLDN-1 was mobile at the tight junction in 
HepG2 cells, and 40% in MDCK cells (Shen 2008). 
 
GPI appeared to diffuse at a lower speed than previously described, with a median of 0.06 
μm2/s in comparison to 1.2+/- 0.2 μm2/s , (Barreiro et al. 2008).However, the quoted speeds 
were calculated in HUVECs, and therefore these differences may be due to differences 
between cell types. In contrast the mobile fraction was much higher in HepG2 cells, 64.94% 
in comparison to <10% in HUVECs. 
Receptor Diffusion 
coefficient 
(μm2/s) 
Reported 
diffusion 
coefficient 
(μm2/s) 
Mobile 
fraction 
(%) 
Reported 
mobile 
fraction (%) 
Cell type Reference 
SRB1 Filopodia: 
0.29  
PM:0.26  
 Filopodia: 
46 
PM: 51.50 
   
CD81 Filopodia: 
053  
PM: 0.23  
- Filopodia: 
46.48 
PM: 53.77 
- - - 
CLDN-1 Filopodia 
0.22  
PM:0.35  
Tight 
junction: 
0.26 
Tight 
Junction: 
0.01  
Filopodia: 
50.19 
PM: 74.50 
Tight 
junction: 
33.14% 
Tight 
Junction: 40 
PM: 0 
MDCK Shen et 
al., 2008  
Occludin Tight 
Junction: 
0.38  
PM: 0.58  
Tight 
Junction: 
0.01 
PM:0.1  
Tight 
junction: 
7.75 
PM: 11.17 
Tight 
Junction: 80 
PM: 20 
MDCK Shen et 
al., 2008  
 
 
 
Table5: Comparison of diffusion kinetics presented in this study and those from previously 
published data 
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4.3 Addition of viral glycoproteins 
 
The soluble viral glycoproteins sE2 and sE1E2 were added to assess their affect on receptor 
dynamics. If considering only the broad groupings seen in figure 12, the two treatments had 
similar effects on both CD81 and CLDN-1; addition of sE2 caused a significant decrease in 
mobile fraction at the filopodia, and addition of sE1E2 caused an increase in diffusion 
coefficient at both. However, for this latter point only the data for CD81 showed a significant 
change. 
 
When the regions of interest were expanded to include exploratory and cell contact regions, 
it became obvious that the majority of the effects mediated by addition of the glycoproteins 
occurred with CLDN-1. The mobile fraction of CLDN-1 was increased and the diffusion 
coefficient decreased by addition of sE1E2 at both exploratory regions; and addition of 
addition of sE2 also caused a decrease in the protein at the exploratory PM and an increase 
at filopodia. In contrast, there were few effects observed on addition of the glycoproteins to 
cells expressing CD81.  In these cells, addition of sE2 and sE1E2 caused a decrease in mobile 
fraction at the cell contact PM and filopodia respectively, and addition of sE1E2 increase the 
mobile fraction of CD81 at areas of high protein expression.  
 
Therefore, the majority of the effects of glycoprotein addition were in the areas of cell 
contact or exploratory regions of the cells, particularly at the filopodia. CLDN-1 and CD81 
were both visible in the filopodia (Figure 4), and engagement of CD81 has been shown to 
activate the Rho GTPase, Cdc42, which coordinates actin cytoskeletal rearrangements in a 
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manner which is complimentary to infection (Brazzoli et al., 2008). Engagement of CD81 has 
been shown to result in the movement of CD81 to areas of cell contact (Brazzoli et al. 2008) 
and therefore, the decrease in mobile fraction of CD81 at the cell contact plasma membrane 
may relate to this movement. Additionally, the changes in diffusion coefficient and mobile 
fraction of CDLN-1 at areas other than cell contact following addition of the viral 
glycoproteins may be caused by the relocation of CD81 causing a breakdown of CD81-CLDN-
1 receptor complexes as the protein moves.  However, Harris et al., (Harris et al., 2008) 
showed that in Huh-7.5 cells addition of sE1E2 did not increase or decrease the 
colocalisation of the proteins, but it did decrease the distance between the two. However, 
these interactions may differ in a more polarised cell line.   
 
Additionally, filopodia form downstream of Cdc42 (Ridley et al., 2011); and therefore 
engagement of CD81 leading to cytoskeletal rearrangements may lead to an increase in the 
number of filopodia per cell.  This may cause a change in receptors dynamics at the cell 
surface, as we have shown previously that receptor dynamics at the PM are different to 
those at the filopodia for these two proteins. 
 
Addition of ITX5061 and ITX7094 
 
Whether ITX5061 acts as a functional or structural inhibitor is unknown. As it reduces HCV 
binding to hepatoma cells, the drug certainly appears to impair structural interactions (Syder 
et al. 2011). Furthermore, evidence suggests that the structural interaction between sE2 and 
SRB1 is important (Scarselli et al., 2002; Syder et al., 2011).   
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However, there is a large amount of evidence supporting the importance of lipoproteins in 
HCV infection, with HDL addition enhancing infectivity and cholesterol depletion reducing it 
(Syder et al., 2011). ITX5061 promotes plasma HDL levels in human and animal models, 
apparently by preventing their catabolism without increasing LDL or very low density 
lipoproteins (vLDL) (Masson et al. 2009). Furthermore, in vitro data show addition of ITX5061 
to reduce SR-BI-mediated HDL lipid transfer (Masson et al., 2009) and ITX5061 will only 
inhibit forms of SR-BI which can bind HDL or LDL (Gu et al. 2000).  
Therefore, it has been suggested that ITX5061 may mimic oxidised lipid species, as oxLDL has 
been shown to inhibit HCV infection in an SR-B dependent manner (Bartosch et al., 2005; 
Voisset et al., 2005; von Hahn et al., 2006).  
This study shows addition of ITX5061 to decrease the mobile fraction of SR-BI at areas of cell 
contact and exploratory regions, whereas effects on CD81 and CLDN-1 are restricted to the 
diffusion coefficient, increasing it at areas of ‘free’ PM and exploratory regions.  
As addition of cholesterol to a membrane decreases its fluidity, a decrease in cholesterol 
transfer into the membrane relative to the control would have the effect of increasing the 
diffusion coefficient of proteins within the membrane, possibly across all structures. 
Although only those values at the exploratory region and free filopodia showed significant 
increases, all diffusion coefficients increased for CD81 and CLDN-1. This suggests a global 
change in membrane composition, possibly through the lipid metabolism function of SR-BI.  
However, the diffusion coefficients of SR-BI did not vary so uniformly, with all apart from the 
PM and exploratory filopodia decreasing in diffusion coefficient. This may suggest that 
although there is a global effect on membrane composition, a specific effect on SR-BI activity 
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is mediated by ITX5061 binding which causes its diffusion coefficient to be altered. This may 
reflect the possibility that SR-BI can create distinct microdomains within the membrane.  
The specific effects of ITX5061 on areas of cell contact or exploratory regions is interesting, 
as SR-BI is particularly important in cell-cell transmission (Brimacombe et al., 2011). The 
changes in mobile fraction may represent a structural change in SR-BI following binding to 
ITX5061, causing a change in the way in which SR-BI interacts with other proteins in the 
membrane or the cytoskeleton.  
 
 
 
 
 
 
 
 
 
 
 50 
 
  
 
Figure 15: Trends observed from data presented in this report. Structures examined in this 
report (a). Trends observed (b). Colour coding is as follows: light blue. Non significant 
decrease; dark blue, significant decrease; light red, non-significant increase; dark red, 
significant decrease; grey, no change.  
Free
Cell contact PM
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and filopodia
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structures
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Figure 15 shows the trends in receptor dynamics highlighted by this study. Although there 
are changes in receptor dynamics at between different cellular locations in all proteins 
studied, the majority of these are non-significant. Addition of the viral glycoproteins sE2 and 
sE1E2 affect CLDN-1 predominantly, and particularly at areas of exploratory contact, where 
the diffusion coefficient is decreased and mobile fraction increase. In contrast addition of 
these glycoproteins had little effect on CD81.  
Addition of ITX5061 caused changes in the mobile fraction only of SR-BI, and in the diffusion 
coefficient only of CD81 and CLDN-1, although across a variety of structures.  
 
In this report we describe the kinetics of the four receptors essential for HCV entry - SRB1, 
CD81, CLDN-1, and occludin. We show that these differ between cellular structures and are 
altered by the addition of the viral glycoproteins sE1E2 and the SRB1 inhibitor SRB1. The 
activity of viral receptors is essential to understanding the mechanism of HCV and will be 
useful in the development of therapies.  
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ABSTRACT 
Life act is a 17aa yeast-derived actin binding protein which has been shown to effectively 
label F-actin both in vivo and in vitro (Reidl et al., 2008; 2010). The lifeact-GFP transgenic 
mouse has been shown to be phenotypically normal and to express the transgene in 
platelets, and thus offers a potentially viable model for the real-time observation of platelet 
actin dynamics. This has not previously been possible due to technical reasons.  
This study aimed to verify the use of the lifeact-GFP transgenic mouse as a model for 
studying platelet actin dynamics in real time. In addition, transgenic platelets were used to 
further characterise actin nodules – punctate areas of dense actin staining (Calaminus et al., 
2008) with an as yet undefined function. It is possible that they have a role in actin 
remodelling, adhesion, or endocytosis.  
The results of this study show that lifeact-GFP platelets are phenotypically similar to wild 
type platelets in terms of their aggregation and morphology during spreading. Therefore, 
they appear to constitute a valid model for further observations. In addition, using live 
imaging this study shows actin nodules to be relatively stationary structures with finite 
lifespans of 87 seconds. Their lifespan appears to be related to filopodia formation, and 
therefore they may mark the positions at which filopodia will form. Using 
immunofluoresence staining, this report shows actin nodules to colocalise with a number of 
focal adhesion proteins suggesting that actin nodules may have a role in adhesion. Finally, 
we show actin nodules do not to colocalise with the endocytosis protein clathrin, and their 
frequency is not affect by addition of the dynamin-mediated endocytosis inhibitor Dynasore. 
Taken together, these data suggest that actin nodules provide a site for the initiation of 
  
 
filopodia formation and may additionally play a role in adhesion of the developing filopodia 
to the extra cellular matrix. 
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INTRODUCTION 
 
1.1 Platelets  
Platelets are anucleate cell fragments which circulate in the bloodstream and become 
activated following contact with areas of damaged vessel wall. As a result of activation 
platelets spread, resulting in an increased surface which allows them to provide a physical 
barrier to blood loss from injured endothelial tissue. In addition, they form a surface area to 
which further platelets can adhere. A second result of activation is the secretion of 
prothrombotic factors, which allows activated platelets to initiate haemostasis by providing 
a surface on which thrombin is generated and fibrin can accumulate (Brass 2010). 
Additionally, platelets contribute to primary immunity by helping to trap bacteria in 
neutraphil-derived DNA nets, and stimulate angiogenesis and contribute inflammatory 
mediators (reviewed in (Leslie).   
 
1.2 Mechanisms of platelet activation 
Following injury and endothelial denudation, the subendothelial extracellular matrix is 
exposed to blood flow. Exposed collagen accumulates circulating von Willebrand Factor 
(vWF), which makes contacts with the platelet GPIb-IX-V complex (Ruggeri et al., 2007). 
These contacts are transient due to the fast on/off-rate of the interaction but are efficient at 
the high levels of shear present in blood vessels (Doggett et al. 2002).  
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The transient binding of vWF to GPIb-IX-V slows the speed of platelet movement sufficiently 
during rolling to allow binding of the low affinity immunoglobulin platelet surface receptor 
GPVI with exposed laminin and fibrillar collagen types I and III (Denis et al. 1998). This 
interaction clusters GPVI at the platelet surface (Inoue et al. 2006) and activates the 
platelets through inside-out signalling via integrins. The principal integrins involved in 
platelet activation are αIIbβ3 and α2β1, the former binds to VWF, fibronectin, and fibrinogen 
(Shattil et al., 2004) and the latter to collagen (Sarratt et al. 2005).  
Inside-out signalling leads to cytoskeletal remodelling, granule secretion, and thromboxane 
A2 formation (TxA2) (Nieswandt, et al 2003). In addition, during this process the weak 
interactions formed between the platelet and the matrix are converted to stable adhesions. 
This increases the net affinity of collagen for GPVI, thus initiating a positive feedback loop of 
activation signals through this receptor (Shattil and Newman 2004).  
Signalling through αIIbβ3 is central to the cytoskeletal rearrangements which occur during 
platelet spreading. Downstream signalling from αIIbβ3 through Src kinases and Syk activates 
second messenger proteins such as protein kinase c (PKC) and Ca2+ (Miranti et al. 
1998;Thornber et al. 2006) and these lead to the assembly of actin structure such as 
lamellipodia, stress fibres, and filopodia (McCarty et al. 2005). 
Following initial adhesion, platelets secrete dense granules and activate phospholipase A2, 
leading to the release of adenosine diphosphate (ADP) and the formation of TxA2 (Nieswandt 
and Watson 2003). These two act synergistically to mediate additional platelet aggregation 
through further platelet tethering, activation and aggregation. Activation and haemostasis is 
further promoted by the generation of thrombin through the coagulation cascade which 
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activates platelets through platelet activated receptors 1 and 4 (PAR1 and PAR4) (Adam et 
al. 2003; Weeterings et al. 2006), and strengthens the clot by cleaving fibrinogen to fibrin. In 
addition, under high rates of shear, platelets shed part of their membrane, leaving trials of 
procoagulant microparticles (Reininger et al. 2006).  
Therefore, there are two principal pathways through which platelets may become activated. 
The first is initiated by GPIV, and results in full platelet activation. The second is initiated by 
the stimulation of heterotrimeric G-protein coupled receptors by thrombin, ADP, and TxA2. 
The first and second pathways proceed through phospholipase C γ2 (PLCγ2) and 
phospholipase Cβ (PLCβ) respectively (Stegner and Nieswandt 2011), both of which lead to 
calcium mobilisation and PK activation. Both PLCγ2 and PLCβ activate the Rho/Rho-kinase 
pathway, which goes on to phosphorylate myosin light chain and contributes to platelet 
shape change (Stegner and Nieswandt 2011).  
 
1.3 Actin 
Actin is a highly conserved 42 kDa protein, and is the most abundant protein in most 
eukaryotic cells. It exists in globular (G) and filamentous (F) forms, with G-actin being a 
double helical polymer of G actin subunits, and F-actin a polymer of these. F-actin filaments 
are polar in nature with a fast-growing (+) end to which monomers are added and a (-) end 
from which monomers disassociate.  
The actin cytoskeleton is vast and extends throughout the cell, and can therefore alter cell 
morphology by assembling and disassembling polymers. In order to ensure a high level of 
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control of the actin cytoskeleton, actin dynamics are regulated by a large range of actin 
binding proteins (Siripala and Welch 2007a; 2007b), combinations of which produce cell 
type-specific organisation of the actin cytoskeleton.  
The best characterised actin structures are the filopodia, stress fibres and lamellipodia, all 
are of which are present at some point in the transition between resting and activated 
platelets (Hartwig et al., 1992). Also, punctuate areas of intense actin staining have been 
identified during early spreading and are termed actin nodules (see section 1.4.2) (Calaminus 
et al. 2008). 
 
1.4 The platelet cytoskeleton 
1.4.1 The resting platelet cytoskeleton  
The resting platelet is discoid in shape and is contains a cytoskeleton robust enough to 
enable it to withstand the high rates of shear stress present during blood flow. The resting 
platelet cytoskeleton is formed of three main components: a spectrin based skeleton which 
adheres to the inner surface of the plasma membrane (1), a multiple microtubule coils which 
line the axis of the cell (Patel-Hett et al. 2008) (2), and  an actin-based network which fills the 
cytoplasmic space (3).  Platelet stimulation activates nucleation and branching of actin 
filaments, thus remodelling the platelet. 
 
1.4.2 Cytoskeletal reorganisation during activation 
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During cell spreading, filopodia form the initial adhesion sites to the substratum and to 
which focal adhesion complex proteins are recruited (Mattila and Lappalainen 2008). 
Lamellipodia then extend between these as the platelet spreads. Additionally, under shear-
stress filopodia have been observed to form tethers between platelets and VWF in a 
developing aggregate (Maxwell et al. 2006); (Nesbitt et al. 2009).  
When fibrinogen and fibronectin engage with platelet surface receptors such as αIIbβ3, the 
tyrosine kinases Src, Syk and focal adhesion kinase (FAK) are recruited to the cytosolic cell 
surface and promote cytoskeletal reorganisation through activation of PKC and increases in 
intracellular Ca2+ (Mangin et al. 2003). These signals regulate actin polymerisation at the 
platelet membrane to allow the growth and extension of actin structures (McCarty et al. 
2005; Watson et al., 2009).  
 
1.5 Actin structures 
This study is concerned primarily with two actin structures present during platelet spreading 
– filopodia and actin nodules. 
 
         1.5.1 Filopodia  
Filopodia are F-actin-rich fast growing projections (Figure 1a, 1b) orientated such the F-actin 
polymers have the ‘+’ ends face towards the cell membrane (Small et al. 1978). Filopodia 
have roles in a wide range of cellular functions, including cell spreading wound healing, 
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adhesion, movement towards to chemoattractants, and embryonic development (Faix and 
Rottner 2006; Gupton and Gertler 2007). 
There are two independent pathways which potentially lead to the formation of biologically 
distinct filopodia in platelets: the Cdc42 and Rif pathways. The difference in filopodia formed 
by each process may represent specific biological functions (Pellegrin and Mellor 2005). 
 In the first pathway, Cdc42 binds and activates either Wiskott Aldrich Syndrome protein 
(WASP) (Aspenstrom et al. 1996; Symons et al. 1996; Rohatgi et al. 1999; Prehoda et al. 
2000) or insulin receptor tyrosine kinase substrate p53 (IRSp53)  (Yamagishi et al. 2004) 
which activates neural (N-) WASP and Arp2/3, and Mena (Krugmann et al. 2001; Yamagishi 
et al. 2004; Scita et al. 2008). These promote actin nucleation and protect elongating 
filaments from capping respectively. IRSp53 is an inverse Bin/Amphiphysin/Rvs (I-BAR) 
domain protein that resides at the cell membrane and is thought to be involved in 
membrane deformation (Suetsugu et al. 2006; Mattila et al. 2007;Lim et al. 2008). 
In contrast, RIF binds GTP and the formin mDia2, leading to the formation of unbranched 
actin filaments by directly nucleating actin assembly and preventing capping (Ellis and Mellor 
2000; Pruyne et al. 2002; Sagot et al. 2002; Higashi et al. 2008).  
Recent studies have shown that Rac1, Cdc42 and WASP are not essential for platelet 
filopodia formation and full platelet spreading (Snapper et al. 2001; Sukumvanich et al. 
2004; McCarty et al. 2005; Pleines et al. 2010) . Although the findings related to Cdc42 is 
controversial (Akbar 2011).  Therefore, the second pathway or another may be the major 
effector of filopodia formation in platelets, although this remains to be tested. Another 
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potential effector is lipid-phosphatase related protein-1 (LRP1), although again this has not 
been verified (Sigal et al. 2007).  
 
1.5.2 Actin nodules 
A novel actin structure has been described (Calaminus et al. 2008) which is observed during 
early spreading. It consists of punctuate areas of intense F-actin staining (Figure 1a) which 
extend throughout the platelet and are termed actin nodules. These are distinct from other 
actin-rich structures such as podosomes, focal adhesions, focal complexes, invadapodia, 
ruffles, and endocytic vesicles (Calaminus et al. 2008) and are observed on a number of 
different substrates. Their appearance has been shown to be dependent on Src kinase 
activity and actin polymerisation, but is independent of PI3K activity, and inversely 
correlated with Rho-kinase and myosin-II activity. They were also shown to contain Arp2/3, 
Fyn, Rac, and β1 and β3-integrins (Calaminus et al. 2008).  
Whilst actin nodules have been shown not to be involved in exocytosis (Calaminus et al. 
2008), it is possible that they are involved in endocytosis. Whilst platelets are adhered to the 
substratum, they endocytose fibrinogen from the plasma pool and traffic it to α-granules, in 
a process which is thought occur by clathrin-dependent receptor-mediated endocytosis and 
the integrin αIIbβ3. However, the mechanism is relatively undefined and needs further study 
(Handagama PJ 1987;  Harrison et al. 1989).  
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1.6 Lifeact 
Actin dynamics may be monitored by the expression of actin-green fluorescent protein (GFP) 
fusion proteins or by injection of fluorescently labelled actin. However, all reported actin 
fusion proteins are functionally impaired and rely on non-tagged actin to buffer the effects 
(Yamada et al. 2005). In addition, the technique is limited to cells which can be transfected 
and therefore it is unsuitable for use in platelets. Permeabilisation of fixed cells followed by 
staining with the fungal F-actin binding protein phalloidin has proved a viable method for 
investigating actin dynamics in platelets however the fixing processes removes the 
possibility of using phalloidin in live cell imaging, and results in the appearance of staining 
artefacts.  
 
Figure 1: Actin nodules and filopodia. Representative images of filopodia (white 
arrows) and actin nodules (white arrowheads) in lifeact-GFP mouse platelets using 
confocal micrscopy (a). Additionally, filopodia are displayed (black arrows) using 
differential interference contrast (DIC) microscopy (b). Confocal images were taken on a 
Leica DM IRE2 confocal microscope and DIC images were captured on a Zeiss Axiovert 
200 M microscope. 
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Lifeact was first described in 2008 (Riedl et al. 2008). It is an actin binding protein encoded 
by a 17 amino acid peptide from Saccharomyces cerevisiae with the sequence 
MGVADKLIKKFESISKEE. A C-terminal fusion transgene of this peptide to fluorescent proteins 
has been shown to act as an efficient label of F-actin in vivo due to the small size of the 
peptide and its absence from higher organisms (Riedl et al. 2008).  
Lifeact offers a considerable improvement upon previous systems for monitoring actin 
dynamics as its low F-actin binding affinity does not cause any major adverse biological 
effects on actin dynamics (Riedl et al. 2008). Furthermore, transgenic mice carrying a lifect-
fluorescent protein fusion have been shown to be phenotypically normal, viable, fertile, and 
to express the transgene in platelets (Riedl et al. 2010).  This makes it a promising candidate 
for studying actin dynamics in live platelets. 
 
 
1.7. Aims 
In this study, I aim to validate the use of the Lifeact-GFP transgenic mouse model as a system 
for studying platelet actin dynamics in real time, and to use this model to study the 
relationship between actin nodules and filopodia. I hypothesise that actin nodules play a key 
role in platelet spreading, possibly by acting as a precursor to the formation of other actin 
structures such as filopodia.  
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2. MATERIALS AND METHODS 
 
2.1 Use of animals 
All animal studies were conducted in accordance with Home Office protocols in compliance 
with project license 30/2721. All animal handling was done by a licensed individual. 
 
2.2 Terminal bleeding of mice 
Lifeact-GFP and C57Blk6 (wild type, WT) mice were culled by inducing unconsciousness with 
isofluorane anesthesia followed by CO2 asphyxiation. Whole blood was then collected into a 
1 ml syringe containing 100μl acid citrate dextrose (ACD) with a 25 ml gauge needle from the 
thoracic aorta.  
 
2.3 Preparation of mouse platelets 
Whole blood from terminally narcosed mice was centrifuged at 200g for 6 minutes and the 
platelet rich plasma (PRP) was collected. After addition of 200μl of Tyrodes buffer ( NaCl, 134 
mM; KCl, 2.9 mM; Na2HPO4.12H2O, 0.34 mM; NaHCO3, 12.0 mM; HEPES, 20.0mM; MgCl2, 
1.0mM) to the PRP, it was centrifuged 3 times at 200g for 6 minutes and each time the PRP 
removed until no more was visible. The final PRP was spun at 1000g for 5 minutes with 
1mg/μl prostaglandin added. The resulting pellet was resuspended in 200μl of Tyrodes 
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solution at pH 7.7. This was diluted to a concentration of 2x107/ml in Tyrodes buffer at pH 
7.3 for use in all experiments. 
2.4 Preparation of human platelets 
Human venous blood was drawn by venipuncture from healthy volunteers into sodium 
citrate and acid citrate dextrose. PRP was prepared by centrifugation of whole blood at 200g 
for 20 min. The platelets were then isolated from PRP by centrifugation at 1000g for 10 min 
in the presence of prostacyclin (0.1μg/ml). The pellet was resuspended in modified 
HEPES/Tyrodes buffer containing 0.1 μg/ml prostacyclin. The platelets were washed once via 
centrifugation (1000g for 10 min) and resuspended at 2x107 with HEPES/Tyrode buffer. 
2.5 Aggregation 
Platelet aggregation of wild type or lifeact-GFP platelets was monitored using 300 ml of 2 x 
108 /ml PRP stimulated with ADP (AltaBiosciences, 3mM), rhodocytin (AltaBiosciences, 
30nM), PAR4 peptide (AltaBiosciences, 250mM) or C-reactive protein (CRP) (AltaBiosciences, 
3mg/ml). Stimulation of platelets was performed in a Chrono-Log aggregometer (Chrono-
Log, PA, USA) with continuous stirring (1200 rpm) at 37 °C as previously described (McCarty 
et al. 2005). 
2.6 Inhibitor testing 
Platelets collected as above (section 2.3) were used at a concentration of 2x107/ml and 
incubated with inhibitors for 5 minutes before plating.  Cytochalasin D (250255, Calbiochem) 
was used at 10uM, Dynasore (D7693, Sigma-Aldrich) at 50μM, and the Arp2/3 inhibitor 
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compound CK666 and relevant control CK689 (Merck Biosciences 182515 and 182517 
respectively) were used at 20μM. DMSO (D8418, Sigma) at 0.1% and 0.3% was used as. 
2.7 Phalloidin-FITC/Rhodamine staining 
Coverslips were incubated with 100μg/ml fibrinogen overnight at 4°C or for 1 hr at room 
temperature (RT) before being incubated with 5mg/ml bovine serum albumin at room 
temperature (RT) for 30 minutes. Platelets were then added at 2x107/ml and fixed in 10% 
neutral buffered formalin solution (Sigma Aldrich, 7K189R5).  
Platelets were permeablilised using 100μl of 50mM NH4Cl for 10 minutes at RT, before being 
washed in PBS incubated at RT for 5 minutes in 0.1% Triton at RT. Following a further wash, 
Phalloidin-FITC/Rhodamine (A12379, Invitrogen and R415, Invitrogen) and  was added at a 
concentration of 4μg/ml and 2 μg/ml respectively for 30 minutes at RT, washed in PBS, and 
mounted in hydromount (National Diagnostics, HS-106) and being stored at 4°C in PBS. 
2.8 Immunofluorescence staining 
Platelets were collected (section 2.3 and 2.4) and fixed in 10% neutral buffered formalin 
solution (Sigma Aldrich, 7K189R5). These were then treated with NH4Cl for 10 minutes at 
room temperature and 0.1% Triton for 5 minutes at room temperature to prepare the 
platelets for staining. They were then incubated with primary antibodies to clathrin (BD 
Biosciences, 611784) at 0.125 μg/ml, pFAK (611722 10/200BD Biosciences) at 1.25 μg/ml, 
paxillin (610569, BD Transduction Lab, UK) at 1.25μg/ml, vinculin (abcam, ab11194) at 0.05 
μg/ml, p34 (7-227, Millipore) at 0.002μg/ml and talin (abcam, ab57758) at 0.002 μg/ml. 
Control antibodies for mouse (Santa Cruz, SC-2025) were used at 0.8 μg/ml, and for rabbit 
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(Santa Cruz, SC-2027) 0.8 μg/ml. Secondary antibodies to mouse (A10680, Invitrogen) and 
rabbit (A11008, Invitrogen) were both used at 4μg/ml and for 30 minutes at room 
temperature before washing and fixing with formalin before mounting. Both rabbit and 
mouse control IgGs were used at an appropriate concentration (1:500 for each). 
 
2.9 Platelet imaging 
For imaging, platelets were used at a concentration of 2x107/ml. Where real time 
microscopy was used, platelets were suspended in pH 7.3 Tyrodes buffer. 
2.9.1 Differential interference contrast (DIC) microscopy 
DIC images were captured with a Zeiss 63x oil immersion 1.40 NA plan-apochromat lens on a 
Zeiss Axiovert 200 M microscope. Digital images were captured by a Hamamatsu Orca 285 
cooled digital camera (Cairn Research, Kent, UK) using Slidebook 5.0 (Intelligent Imaging 
Innovations, Inc.,). 
 2.9.2 Confocal microscopy 
Confocal images were taken on a Leica DM IRE2 confocal microscope illuminated using the 
488 line of an argon laser and a 63x 1.4Na oil immersion objective. 
  2.9.3 Total internal reflectance fluorescence (TIRF) microscopy 
TIRF images were captured on a Nikon A1R confocal / TIRF microscope using with a 60x 1.49 
NA objective and an Andor iXion EM-CCD. 
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2.10 Image manipulation 
Where necessary, images were cropped and overlayed using ImageJ image processing 
software. Also, the cell counter (Kurt de Vos, University of Sheffield) and manual particle 
tracking (Fabrice Cordelieres, Institut Curie) add-ins were used.   
2.11 Statistics 
Statistical analyses and data representation were carried out using GraphPad Prism software 
(GraphPad software, San Diego), with significance calculated using the Student’s T test with 
a Mann-Whitney post test: p < 0.05 (*), p< 0.01(**), and p < 0.001 (***). All values quoted 
are means unless otherwise stated. 
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3.0 RESULTS 
 
3.1 Lifeact-GFP transgenic platelets display similar aggregation curves to WT platelets 
Lifeact-GFP mice were observed to have no obvious visual or behavioural defects in 
comparison to WT mice and were born at normal Mendelian ratio.  In order to investigate 
whether Lifeact-GFP platelets are defective, PRP was collected from a mouse expressing the 
Lifeact-GFP transgene and from a control WT mouse. Platelet aggregation was performed 
following addition to PRP of ADP (3μM, Figure 2a), CRP (3μg/ml, Figure 2b), rhodocytin (30 
μM, Figure 2c), and PAR4 peptide (250μM, Figure 2d). These showed aggregation to be 
similar in both backgrounds, indicating that expression of lifeact-GFP does not aberrantly 
affect the platelet function.  
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Figure 2: Aggregation of wildtype and lifeact-GFP platelets. Platelets 
from WT and lifeact-GFP mice were stimulated with ADP at 3μM (a) 
CRP at 3μg/ml (b) rhodocytin  at 30 μM (c) PAR4 peptide at 250μM (d). 
Aggregation traces were produced on Chrono-Log aggregometer. 
(Chrono-Log, PA).  
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3.2 Platelets undergo a series of distinct stages during platelet spreading, and these are 
replicated in lifeact-GFP transgenic mice 
That platelets undergo a series of distinct morphological changes upon a fibrinogen-coated 
surface has been well documented (Hartwig et al.,1992) (Figure 3a-e). In the present study, I 
compared the morphological changes occurring in control platelets (Figure 3a-e) to those 
from lifeact-GFP platelets upon adhesion to fibrinogen.  
On initial contact, platelets could be seen to have an occasional filopodia and usually no 
more than one actin nodule (Figure 3 a, f, k). With time, further filopodia and actin nodules 
appear (Figure 3 b, g, l,  and c, h, m) followed by the generation of lamellipodia (Figure 3 d, i, 
n) and stress fibres (Figure 4 e, j, o).  
Therefore, using epifluoresence microscopy platelets from WT and lifeact-GFP mice were 
observed to undergo a similar pattern of spreading on fibrinogen (Figure 4 f-j, k-o).  
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Figure 3: Distinct stages of platelets spreading. The distinct stages in platelet spreading 
(a-e)  begin with initial contact on contact with a substrate (a) followed by development 
of initial actin nodules and filopodia (b), development of further nodules and filopodia (c) 
formation of lamella (d), and formation of stress fibres (e) (DIC images were captured on 
a Zeiss Axiovert 200 M microscope) . These patterns are replicated by fixed phalloidin-
stained WT platelets (f-g) (Images taken using a Zeiss Axiovert 200 M microscope) and in 
lifeact-GFP transgenic platelets  (k-o) (TIRF images were imaged live on a Nikon A1R 
confocal / TIRF microscope).  
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3.3 Actin nodule size 
In order to establish the morphological similarities between actin nodules in WT and lifeact-
GFP transgenic platelets, the diameter of actin nodules in each background was measured 
(Figure 4a). This revealed no significant difference in sizes between the two, although those 
in lifeact-GFP platelets were slightly larger (Figure 4a) than those of WT. Actin nodules in WT 
platelets had a median diameter of 0.46 μm (SD 0.12 μm), whereas those from lifeact 
platelets had a diameter of 0.57 μm (SD 0.16 μm). 
 
 
3.4 Actin nodules appear to have a limited lifespan 
To examine the expression of actin nodules in more detail, the number of actin nodules per 
platelet was recorded each minute following initial contact with a fibrinogen substrate. The 
initial number of actin nodules is 2.5 per platelet at first contact, which increases to around 4 
per platelet after 2 minutes. This number remains constant and does not increase with time 
(Figure 4b) suggesting that actin nodules may have a finite lifespan. Therefore, the average 
lifetime of actin nodules was measured and found to be 87 seconds (SD 4.23 seconds) 
(Figure 4c); although the majority of nodules had a lifetime of 30-60 seconds with a range of 
17.5-180 seconds (Figure 4c). Therefore, actin nodules appear to have a finite lifespan.  
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3.5 Dependence on actin nucleation and polymerisation 
In order to establish the dependence of actin nodule formation on actin nucleation and 
polymerisation, the Arp2/3 inhibitor CK666 (20uM), control compound CK689 (20uM), and 
the actin polymerisation inhibitor cytochalasin D (10 μM) were added to lifeact-GFP 
transgenic platelets prior to spreading (Figure 5). 0.1% DMSO was used as a control. 
Quantification of the number of actin nodules (Figure 5a) and filopodia (Figure 5b) per cell 
showed that addition of compound CK666 decreased the number of filopodia and nodules 
per cell in comparison to both CK689 and the DMSO control.  
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Figure 4: Basic characteristics of actin nodules. Median diameter of actin nodules in 
WT and lifeact-GFP platelets  (n=39) (a).  Mean number of actin nodules present per 
platelet per minute in lifeact-GFP mouse platelets (n=16) (b). The average lifespan of 
actin nodules in lifeact-GFP mouse platelets (mean = 87 seconds, SD = 4.64, n=34) at 
half-minute intervals following initial attachment of platelets to substrate (c). All 
observations  made from images taken on a Nikon A1R confocal / TIRF microscope.  
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Addition of cytochalasin D inhibited entirely the formation of filopodia (Figure 5d), and also 
decreased the number of nodules to a similar level as those in platelets which had been 
treated with compound CK666 (Figure 5a). 
Actin nodules in platelets treated with either CK666 or cytochalasin D appeared to be larger 
and more diffuse than those treated using control compounds (Figure 5 d and e compared to 
f and g). Therefore, the diameter of actin nodules was measured in all four populations 
(Figure 5c). This showed actin nodules in platelets treated with CK666 to be significantly 
larger than those treated with DMSO. Similarly, actin nodules in platelets treated with 
cytochalasin D also had a significantly larger diameter to those treated with DMSO (Figure 
5c, d).   
These data show that the formation of actin nodules and filopodia requires both actin 
polymerisation and Arp2/3-dependent nucleation.  
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Figure 5: Dependence of actin nodules and filopodia on  Arp2/3-dependent 
nucleation and polymerisation in lifeact-GFP platelets. Number of actin nodules (a) 
and filopodia (b) per cell after addition of DMSO (0.1%), the Arp2/3 inhibitor CK666 
20μM , relevant control compound CK689 μM, and cytochalasin D (10μM). Diameter 
of actin nodules following addition of these compounds (c).  Appearance of platelets  
and actin nodules (white arrowheads) following addition of DMSO (d) the inhibitors 
CK689 (e) and CK666 (f) and cytochalasin D (g). N<15 for each compound.  
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3.6 Actin nodules appear to be associated with filopodia 
Following live imaging of Lifeact-GFP platelets it was noted that actin nodules appear to be 
localised to the base of filopodia (Figure 6a), therefore the relationship between actin 
nodules and filopodia was explored further. Initially, the region at the base of a filopodia was 
examined for 10 seconds before and after filopodia formation for the presence of an actin 
nodule (Figure 6b). This showed that in the majority of cases, an actin nodule was present 
prior to filopodia formation, and in around 50% of cases this nodule was present more than 
10 seconds prior to filopodia formation (Figure 6b). This led us to further examine the 
development of the two structures by looking at the relationship between the two from the 
initial contact of the platelet with fibrinogen. In particular, the time at which an actin nodule 
appeared before filopodia formation was observed (Figure 6c), and the time after filopodia 
formation for which the nodule persists (Figure 6d). This revealed a peak in actin nodule 
formation 10 seconds before filopodia formation (Figure 6c), and that the majority of actin 
nodules disappeared within 75 seconds of filopodia formation (Figure 6d).  Taken together, 
the data presented here allowed a schematic of the average lifespan of an actin nodule to be 
drawn (Figure 6e).  This showed that actin nodules appear on average 18 seconds (SD 1.94 
seconds) before a filopodia forms, and persist for an average of 69 seconds (SD 0.91 
seconds) after filopodia formation, giving a mean lifespan of 87 seconds (SD 4.23 seconds).  
These data show actin nodule lifespan to coordinate with filopodia formation. 
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Figure 6 - Relationship between actin nodules and filopodia in lifeact-GFP mouse 
platelets. Actin nodules appear to be located at the base of filopodia (a) Time of 
actin nodule appearance in relation to filopodia appearance (n=85) (b), frequency 
of actin nodules appearing per second before filopodia appearance (n=32) (c), and 
frequency of actin nodule persistence following filopodia appearance (n=32) (d). 
Schematic of actin nodule lifetime (e). 
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3.7 Dynamics of actin nodule movement 
To determine if actin nodules move towards the filopod with which they are associated or 
whether they remain static, the particle tracking plugin for ImageJ (Fabrice Cordelieres, 
Institut Curie) was used to follow their movement (Figure 7a) over time (Figure 7 b-j). The 
resulting plots showed that actin nodules appear to remain relatively static with only small 
random movements being observed (Figure 7 b-j), which are usually around half of their own 
length (<0.2μm). Therefore, it appears that actin nodules are relatively static and may 
represent adhesions or anchor points for filopodia.  
 
3.8 Colocalisation of focal adhesion proteins with actin nodules 
As actin nodules remain static at the base of filopodia, it is possible that they are equivalent 
to focal adhesions, albeit somewhat smaller in size.  To investigate this, fixed human 
platelets were counterstained with FITC-phalloidin, and stained with antibodies to a number 
of focal adhesion proteins; the actin binding proteins vinculin, paxillin, p34, and talin, the 
integrin subunit αIIb, and the focal adhesion protein pFAK (Figure 8 a-f).  The subunit of the 
Arp2/3 complex was used as a positive control for actin nodules, as they have been shown to 
contain it (Calaminus et al. 2008). The results showed actin nodule colocalisation with 
vinculin (Figure 8a), paxillin (Figure 8b), p34 (Figure 8d), talin (Figure 8e), and αIIb (Figure 8f), 
although they did not colocalise with pFAK (Figure 8c).  
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Therefore, actin nodules contain a number of proteins found at focal adhesions indicating 
that they may play a role in anchoring the platelet to the to the substrate and provide 
initiation points for filopodia formation.  
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Figure 7: The assocaition between actin nodules and filopodia in lifeact-GFP 
platelets. Particle tracking of an actin nodules using ImageJ. Each coloured line 
represents the trajectory of a single actin nodule (a).  The directionality of actin 
nodule movements. Blue arrows represent the direction of movement of actin 
nodules at the last measured point and black arrows represent the angle of 
filopodia emergence from the associated actin nodule (b-i).  
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3.9 Markers of endocytosis  
It has been shown that actin nodules do not have a role in exocytosis (Calaminus et al. 2008), 
but it is possible that actin nodules are involved in endocytosis. Therefore, their relationship 
with dynamin- and clathrin-mediated endocytosis was examined. Using fixed human 
platelets in which the actin had been costained with rhodamine. 
Human platelets containing actin costained with FITC were stained with an antibody to 
clathrin and the two did not appear to colocalise (Figure 9a). Furthermore, addition of the 
dynamin inhibitor Dynasore to lifeact-GFP appeared to have no effect on the number of 
actin nodules per cell (Figure 9b). In addition, quantification of the number of actin nodules 
per cell showed platelets treated with DMSO and Dynasore to have a similar frequency 
distribution of actin nodules per cell (Figure 9c). The peak number of actin nodules for both 
Dynasore and 0.3% DMSO treated platelets was 2 per cell, although the range of actin 
nodules per cell was greater in those treated with 0.3% DMSO (0-7 nodules/cell) than with 
Dynasore (0-12 nodules/cell). 
Therefore, actin nodules do not appear to be involved in dynamin- or clathrin- mediated 
endocytosis.  
Figure 8:  Focal adhesion staining. 488-linked staining of the focal adhesion proteins 
vinculin (a) paxillin (b), pFAK (c), p34 (d), talin (e), and αIIb (f) in human platelets. Actin 
in platelets was costained with rhodamine and intensity normalised to  relevant 
controls. Examples of cells expressing colocalisation are marked by white arrowheads. 
Images taken on a Leica DM IRE2 confocal microscope  and a 63x 1.4Na oil immersion 
objective  
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4. DISCUSSION 
This study aimed to verify the Lifeact-GFP transgenic mouse as a model for studying platelet 
actin dynamics in real time, and to further describe the role of actin nodules in spreading 
platelets. The results of this study show that platelets obtained from mice expressing the 
lifeact-GFP transgene perform similarly to those obtained from wild type platelets in terms 
of platelet spreading and aggregation, and thus they appear to constitute a valid model for 
the visualisation of platelet actin dynamics. Therefore, these platelets were used to 
characterise actin nodules in real time in terms of their lifetime, dynamics, association with 
filopodia and their role in platelet spreading. 
Lifeact platelets presented a considerable benefit to this study, as they allowed live imaging 
of platelet actin within minimal impact on actin dynamics and no artefacts of fixing or 
staining. In addition, live imaging allowed platelet spreading to be examined from the exact 
time of contact with substrate, and thus timing was more exact.  
The functionality of lifeact-GFP platelets was investigated. Platelets were stimulated through 
P2Y1 and P2Y12, GPVI, Clec2, and the thrombin receptor, and their aggregation compared to 
those of WT platelets.  Lifeact-GFP transgenic platelets appeared to aggregate in a normally 
when compared to WT platelets. In vivo experiments were not carried out in the study, but 
mice appeared phenotypically and behaviourally normal with no evidence of clotting 
dysfunction. However, future experiments could determine if bleeding times are affected by 
using a tail bleed assay. Therefore, lifeact platelets appear to constitute a valid model for 
visualising actin dynamics in platelets. 
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Having established that the platelets function normally, their spreading was examined. 
Platelets have been shown to undergo a series of distinct morphological changes during 
platelet spreading (Hartwig et al., 1992), beginning with the appearance of focal adhesions, 
followed by formation of filopodia and culminating in lamellipodia and stress fibre 
formation. The lifeact probe has been shown not to significantly perturb the actin 
cytoskeleton dynamics of a number of cell types including platelets in vitro  or in vivo (Riedl 
et al. 2008; 2010). By comparing the spreading of lifeact platelets with those of fixed 
phalloidin-labelled wild-type platelets, the results presented here show that actin in lifeact-
GFP platelets undergo the same series of changes.  
Actin structures are well characterised; particularly filopodia, lamellipodia and stress fibres. 
In 2008, actin nodules were described as punctuate areas of actin staining present in 
platelets during early spreading (Calaminus et al. 2008).  In order to gain further 
understanding of these structures, the lifetime of actin nodules was investigated and their 
characteristics studied in order to elucidate a possible function. In the original paper, actin 
nodules were shown to contain the actin nucleating complex Arp2/3, the small Tapes Rac, 
Fyn, and the integrins β1 and β3 (Calaminus et al. 2008). Therefore, the authors suggested 
that they may play a role in adhesion or actin remodelling and suggested two of potential 
roles for the structures: (1) reservoir of actin for platelet spreading (2) initial adhesion sites 
or focal adhesion-type structures. However, it is also possible that they have a role in 
endocytosis.  
The average width of an actin nodule does not vary significantly between WT and lifeact-GFP 
backgrounds, and in lifeact platelets the median diameter is 0.57μm. This is smaller than 
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that quoted in the original paper (Calaminus et al. 2008) although this is likely due to the use 
of human platelets in that study, which are considerably larger than mouse platelets. In 
order to confirm that there is no change in size; platelets from both backgrounds could be 
fixed and stained in the same way. 
By using real-time microscopy to synchronise platelet spreading, the results of this study 
show that the peak number of actin nodules form at 3 minutes following initiation of platelet 
spreading and then to remain fairly constant. This suggests that the structures have a finite 
lifetime, which was found to be 87 seconds, although the majority persisted for 30-60 
seconds. This supports previous preliminary data attained using these mice (Amy Davies – 
unpublished) which suggests that the majority of actin nodules persist for 30-60 seconds.  
During preliminary analysis, It was noted that actin nodules appeared to be associated with 
the base of developing filopodia, appearing around 18 seconds prior to the formation of 
filopodia and persisting for on average of 69 seconds following their appearance. The 
correlation of actin nodule lifespan with the formation of filopodia suggested a relationship 
between the two. Therefore, the spatial association of actin nodules and filopodia was 
investigated using particle tracking to determine if the nodules moved towards the 
extending filopodia or remained associated at the base. During the observation time, actin 
nodules appeared to remain relatively stable and moved less than half their own length with 
no apparent directionality. This finding suggests that while an actin nodule does appear to 
be associated with a filopod, it does not seem to actively move towards it. Instead, the small 
movements seen may represent movement of the actin nodule as the platelet spreads. 
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The possibility that actin nodules may be acting as a reservoir of actin for formation of actin 
structures during platelet spreading, specifically filopodia was further investigated. The actin 
polymerisation inhibitor cytochalasin D and the Arp2/3 inhibitor CK666 along with suitable 
DMSO controls were added to lifeact-GFP platelets. Addition of both inhibitors significantly 
decreased the number of actin nodules in platelets but did not ablate their presence 
entirely. This suggests either that a small number of actin nodules are present before 
spreading begins and that no more develop in the presence of these inhibitors, or that the 
effect of these inhibitors is not complete or a small number of nodules may still form in their 
presence.  Interestingly, the actin nodules in the inhibited platelets appeared to be more 
diffuse than those in control samples, and they resembled morphologically actin nodule-like 
structures observed in ‘resting’ platelets i.e. those which have not yet been activated (Dr. 
Steven Thomas, personal correspondence). Measurement of the actin nodules in treated 
platelets showed these to be significantly larger than those treated with control compounds. 
If ‘resting’ platelets do contain actin nodules, it may be that these mature during spreading 
and that inhibition of actin nucleation and polymerisation prevent this.  
These data confirm that both actin nucleation and polymerisation are necessary for the 
development of both structures, but does not confirm that actin nodule are necessary for 
the formation of filopodia. However, both processes appear to be important in the transition 
from ‘resting-type’ to ‘spreading-type’ structures, and suggests that they may be related to 
the function of these structures.  
The stability of actin nodules observed using real-time microscopy suggests that they may be 
related to focal adhesion-like structures. Costaining with focal adhesion proteins showed 
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talin, vinculin and paxillin to be localised with the structures, but not pFAK. Repetition of this 
staining or staining with total FAK may clarify this result. However, the colocalisation of the 
majority of these proteins suggests that actin nodules may be related to focal adhesions. 
These structures generally contain integrins and costaining with antibodies to the major 
platelet integrin αIIbβ3 showed the integrin to be present at these structures. This combined 
with the relatively static appearance of surface nodules indicates that at least some part of 
their role is in adhesion. 
The final possible role of actin nodules is related to endocytsosis. Staining of platelets with 
antibodies to clathrin showed that actin nodules and clathrin did not colocalise. 
Furthermore, treatment with the dynamin-mediated endocytosis inhibitor Dynasore did not 
significantly change the apparent distribution of platelets expressing certain numbers of 
actin nodules. These data suggest that actin nodules are not involved in clathrin or dynamin-
mediated endocytosis, but repetition of clathrin staining using lifeact-GFP platelets is 
needed.  
In conclusion, in this study, I show that lifeact-GFP mice are a suitable model for studying 
platelet actin dynamics, and that actin nodules may play a role in cytoskeletal remodelling or 
adhesion but are not likely to be involved in clathrin- or dynamin-mediated endocytosis. 
During cell spreading, filopodia form the initial attachments to the substrate, to which 
adhesion proteins are recruited (Mattila and Lappalainen, 2008). Therefore, adhesion in 
platelets may be initiated by structures which have the potential to form filopodia, and 
therefore the structures acquire adhesion proteins. Further work to verify this could follow 
the recruitment of these proteins to actin nodules. 
 90 
 
Additional further work could cover a variety of points. It would be interesting to monitor 
cytoskeletal rearrangements under conditions of shear stress to see if the structures 
observed during thrombus formation are dependent on actin nodule formation. In addition, 
observing the relationship between actin nodules and filopodia using epifluorescence 
microscopy may add considerable amounts of information as to the location and movements 
of actin nodules. In this study, total internal fluorescence reflectance (TIRF) microscopy was 
used; a technique in which only 100-200 nm of the platelet in contact with the glass slides is 
illuminated. Whilst this produces a clear image which is easy to interpret, it omits any 
information from further within the cell. Therefore it is possible that actin nodules may not 
disappear but simply move out of the plane of vision.  
A working hypothesis of the role of filopodia based on the data presented here is as follows. 
If the actin nodule-like structures correspond to those observed in spreading platelets, they 
may represent an ‘immature’ actin nodule structure which matures during spreading. If this 
is correct, it may be that actin nodules are recruited to the cell membrane following contact 
of the platelet with a substrate. As the ‘mature’ structures colocalise with a number of 
proteins involved in focal adhesions including integrin αIIb, it could be that contact of the 
platelet with the substrate causes clustering of integrin leading to recruitment of some focal 
adhesion-like proteins to these regions. The result of clustering of integrins is inside-out 
signalling, which has been shown to lead to cytoskeletal rearrangements. These 
rearrangements could lead to morphological changes in the actin nodules and subsequent 
filopodia formation.  
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This hypothesis relies on the actin nodule-like structures within resting platelets being actin 
nodules., Therefore, further work to test this hypothesis would need to repeat the 
characterisations previously carried out in this report and previously (Calaminus et al., 2008) 
in terms of the processes on which these structures are dependent and the proteins with 
which they colocalise. 
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Supplementary Figure 1– Variance in diffusion coefficient and mobile fraction 
between PM and filopodia. Variance in diffusion coefficient and mobile fraction 
between HepG2 cells transfected to express GFP-occludin (n>5) and GFP –GPI 
(n>40) at the PM and filopodia.  Diffusion coefficient and mobile fraction were 
calculated as  previously described using data from Zeiss software. N>15.  
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Median (IQ range) Mean S.D.
Occludin 
diffusion 
coefficient 
(μm2s-1)
PM 0.47 (1.2) 0.58 0.55
Tight 
Junction
0.28 (0.42) 0.38 0.22
Occludin 
mobile 
fraction (%)
PM 10.54 (6.76) 11.17 4.49
Tight 
Junction
7.45 (4.84) 7.75 2.74
GPI diffusion 
coefficient 
(μm2s-1)
PM 0.06 (0.33) 0.26 0.42
Filopodia 0.02 (0.03) 0.09 0.22
GPI mobile 
fraction (%)
PM 64.94 (28.61) 63.96 20.38
Filopodia 50.47 (31.67) 48.62 16.23
Supplementary Table 1: Median, interquartile range (IQ range), mean, and standard 
deviation (S.D) of data presented in Figure 10. HepG2 cells were transfected to 
express GFP-occludin and GFP-GPI and bleached using a Zeiss  Meta head laser 
scanning 780 confocal microscope. Statistics were calculated as previously described 
using data from Zeiss software. n>21.Values calculated using GraphPad Prism 
Software.  
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Supplementary Figure 2: Variance in diffusion coefficient and mobile fraction 
at specific cellular structures. Variance in diffusion coefficient (a)and mobile 
fraction (b) between HepG2 cells transfected to express GFP-GPI at  specific 
locations N>15.  
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Median
(IQ range) Mean S.D
OCLDN 
Diffusion 
Coefficient 
(μm2/s)
Cell contact PM 0.07 (0) 0.23 0.29
Tight junction 0.28 (0.42) 0.38 0.22
OCLN 
Mobile 
Fraction (%)
Cell contact PM 11.52 (8.72) 12.49 5.63
Tight junction 7.45 (4.84) 7.75 2.74
GPI 
Diffusion 
Coefficient  
((μm2/s)
Cell contact PM 0.04 (0.31) 0.24 0.41
Exploratory 
filopodia 0.01 (0.23) 0.19 0.36
Exploratory PM 0.003 (0.02) 0.07 0.19
GPI Mobile 
Fraction (%)
Cell contact PM 79.33 (24.93) 73.84 21.25
Exploratory 
filopodia 53.39 (30.28) 46.57 18.74
Exploratory PM 50.4 (29.95) 51.17 19.03
Supplementary Table 2: Median, interquartile range (IQ range), mean, and 
standard deviation (S.D) of occludin and GPI at specific cellular locations. HepG2 
cells were transfected to express GFP-occludin and GFP-GPI and bleached using a 
Zeiss  Meta head laser scanning 780 confocal microscope.  Diffusion coefficient 
and mobile fraction were calculated as previously described using data from Zeiss 
software. Values calculated using GraphPad Prism Software.  
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